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CHAPTER 1
INTRODUCTION
Breast Cancer
Cancer is a significant threat to the well-being of individuals worldwide. In 2008
it is estimated that 12.7 million new cancer cases were diagnosed and 7.6 million cancer
deaths occurred worldwide [5]. Breast cancer is the most frequently diagnosed cancer in
women worldwide with an estimated 1.38 million cases, and breast cancer is the leading
cause of cancer deaths worldwide being responsible for over 458,400 deaths in 2008 [5].
Breast cancer accounts for 23% of cancer cases and 14% of cancer deaths worldwide in
women making it the leading cause of cancer mortality for all women [5-7].

The

majority of cases of breast cancer diagnosed in the United States are local or regional
stage, while breast cancer diagnosed in developing countries is mostly advanced stage [8,
9]. Based on 5-year prevalence data, breast cancer is the most prevalent cancer with an
estimated 4.4 million women living with breast cancer [6, 7].
In the United States there is predicted to be 1.7 million cases of cancer and there
is expected to be 585,720 deaths due to cancer to occur in 2014 [10]. One in eight
women in America will be diagnosed with breast cancer in her lifetime [11, 12].
Excluding skin cancers, breast cancer is the most common cancer diagnosed among
American women with 232,670 women expected to be diagnosed with invasive breast
cancer in 2014, accounting for 29% of female cancer diagnoses [10]. In addition, over
62,570 women in the United States will be diagnosed with carcinoma in situ of the breast

2

(defined as stage 0 breast cancer [13]) in 2014 [10]. For women, breast cancer is second
only to lung cancer in the number of cancer deaths in the United States [10, 12].
However among women between 20 to 59 years of age breast cancer is the leading cause
of cancer deaths [10]. An estimated 40,000 deaths due to breast cancer are expected to
occur in 2014 accounting for 15% of cancer deaths in American women [8, 10, 14].
Evidence suggests that differences in breast cancer mortality amongst races are due to not
only disparities in epidemiological factors such as educational level, socioeconomic
status and access to care, but also due to a difference in tumor biology and etiology [12,
15-19]. Thus, breast cancer is not one disease, but many diseases emphasizing the need
for individualized treatments. The number of people in the United States living after
having been diagnosed with cancer, cancer survivors, continues to grow, reaching an
estimated 11.9 million cancer survivors in 2008 [20].

Amongst American cancer

survivors, breast cancer is one of the most common diagnoses [20]. The number of
breast cancer survivors was expected to have reached approximately 1.85% of the
population in the United States in 2010 and is predicted to continue growing to over 2%
of the population by 2015 [21]. As the most prevalent cancer and the leading cause of
cancer mortality of women in the world, there is no doubt of the importance of breast
cancer research.
Increasing age is a risk factor for developing cancer [22, 23]. Increasing age is
also a risk factor for the development of breast cancer [24], however breast cancer is
unique in that most breast cancer cases are diagnosed in women under the age of 65 [20,
25]. Furthermore, amongst all primary cancers in women, breast cancer has the highest
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tendency to metastasize [26]. Additionally, breast cancer had the broadest range of
metastatic sites of any cancer according to a large autopsy study of cancers [26]. The
most common sites of metastases of breast cancer primary tumors are to the axillary
lymph nodes, the bone, the liver, and the lungs [27].
Breast Cancer Subtypes
Breast cancers can be categorized by various clinical, pathological, and molecular
characteristics in an effort to determine prognosis and appropriate treatment. At the most
basic level, histological analysis of tumor tissue involves determining the morphology of
the breast cancer. Studies show that more than 80% of invasive breast cancers are ductal
carcinoma, while the remaining invasive breast cancer cases are primarily lobular
carcinoma, or mixed ductal and lobular carcinoma [28-32].
Individuals diagnosed with breast cancer are further evaluated such that the
clinical and pathological stage are be determined [13]. In this process the breast cancer
tumor tissue is assessed for important biological tumor features that are used to help
guide treatment options and provide prognostic or predictive information [13]. Breast
cancer is treated by various combinations of local treatment (surgery and/or radiation
treatment) and systemic treatment (chemotherapy, endocrine treatment, biologic
treatment, or combinations of those) depending upon the evaluation of the tumor tissue
and the stage of the disease [13]. The current standard of care dictates that all cases of
invasive breast cancer should be assessed for the expression of hormone receptors
(estrogen and progesterone, [33-35]) and the expression of the HER2/neu oncogene [13,
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36-39]. Treatment is then guided by tumor histology, disease stage, pathologic tumor
characteristics, axillary lymph node status, multigene assay testing, patient illness, age,
menopausal status, and patient preference [13]. Breast cancers that express the hormone
receptors can be targeted with endocrine treatments thus improving survival (as reviewed
in [40]). Breast cancers that overexpress HER2/neu, while generally thought of as having
a poor prognosis, also have the benefit of targeted treatments available which has
significantly improved their prognosis [41]. However, breast cancers that do not express
the hormone receptors and do not express HER2/neu, known as “triple-negative” breast
cancers, pose a special clinical problem in that there are no targeted treatments currently
available. A better understanding of triple-negative breast cancers is needed in order to
improve the outcome for those breast cancer patients, as targeted treatments have
improved outcomes of hormone receptor positive breast cancer and HER2/neu
overexpressing breast cancers.
Breast cancers have been known to be a heterogeneous group of tumors, however
microarray analysis of gene expression and hierarchal clustering analysis identified five
subtypes of breast cancer tumors: basal-like, HER2/neu overexpressing, luminal A,
luminal B, and normal breast tissue-like subtype [42-44]. Basal-like breast cancers and
triple-negative breast cancers are closely related, overlapping groups of breast cancers (as
reviewed in [45]). Basal-like breast cancers have a triple-negative phenotype by lacking
hormone and HER2/neu receptor expression, however they also express genes associated
with myoepithelial (basal) cells, such as cytokeratin 5 and EGFR giving them their name
“basal-like” (as reviewed in [45]).

HER2/neu overexpressing (ER-negative) breast
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cancer subtype, and basal-like breast cancer subtype had the worst prognosis of any of
the molecular subtypes of breast cancer [46, 47]. With medical advancements since the
discovery of HER2/neu overexpressing breast cancer, there are now the treatments that
target HER2/neu, such as trastuzumab (Herceptin®) available which have significantly
improved the disease-free survival and overall survival for those patients [48]. Basal-like
breast cancers similarly having a natural disease history that confers a poor prognosis [46,
47] still have the added disadvantage of having no targeted therapies available.
Furthermore, Neve et al. analyzed the transcriptional profiles of a set of 51 breast
cancer cell lines, and utilized hierarchical clustering to find clusters similar, but not
exactly the same as the subtypes found in tumor tissue [1]. Their study initially found
two distinct clusters, the Luminal subtype and a basal-like cluster [1]. The basal-like
cluster was then found to have two major subdivisions, termed Basal A subtype and
Basal B subtype [1]. The Basal B subtype was vimentin-positive with stem cell-like
profiles and believed to contain the triple-negative clinical tumor subtypes [1].
HER2/neu overexpressing cell lines were found mixed throughout the Luminal and Basal
A subtypes in this study [1]. This study demonstrated that breast cancer cell lines, like
tumor tissue, are heterogeneous, however clusters with significant similarities have been
found in an effort to identify a molecular basis for the development of future targeted
therapies for breast cancer [1].
Platelet-Derived Growth Factor (PDGF) Family
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PDGFs are members of the cysteine-knot growth factor superfamily (as reviewed
in, [49]). The cysteine-knot superfamily of growth factors comprises several members:
the four PDGF ligands (PDGF A, PDGF B, PDGF C, and PDGF D), the five vascular
endothelial growth factors (VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E) along
with placenta growth factors (PlGF-1 and PlGF-2), NGF, TGFβ, and v-Sis [49, 50]. The
members of this superfamily contain eight conserved cysteine residues [49].

Figure 1. The PDGF family of ligands and receptors. Proteases capable of
proteolytically processing and activating PDGF C and PDGF D are listed. The
ligands and receptors homo-dimerize or hetero-dimerize as depicted.

The platelet-derived growth factor family consists of the four ligands, PDGF A,
PDGF B, PDGF C and PDGF D, in addition to the two PDGF receptors, PDGF Receptor-
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α (PDGFR-α) and PDGF Receptor-β (PDGFR-β) (Figure 1). Their name is derived from
the fact that PDGF was first isolated from platelets ([51-58] as reviewed [59]). These
growth factors form five sets of homo- or hetero-dimeric ligands, PDGF AA, BB, AB,
CC and DD (as reviewed in [60]) (Figure 1).

Platelet-derived growth factors are

mitogens for an array of cell types such as smooth muscle cells, fibroblasts, and glial
cells (as reviewed in [60-62]). The PDGF-Receptors (PDGFRs) are receptor tyrosine
kinases. PDGFRs are known to bind homo- or hetero-dimeric PDGF ligands, inducing
homo- or hetero-receptor dimerization (PDGFR-α/α, PDGFR-α/β, or PDGFR-β/β, Figure
1) resulting in auto-phosphorylation which then leads to signal transduction via several
molecules including PI3K, PLC-γ, Raf-1, GAP, and PKC (as reviewed in [62, 63]).
PDGFRs are expressed in many different cell types including endothelial, epithelial and
neural cells, and are necessary for embryological development (as reviewed in [60]).
Traditionally PDGFs have been believed to function through paracrine signaling with
epithelial cells secreting ligands that act on adjacent stromal cells.
PDGFs & Breast Cancer
Since the simian sarcoma virus oncogene, v-sis, was discovered to be derived
from the PDGF gene ([64, 65] as reviewed in [66]), PDGFs have been implicated in
many cancers (as reviewed in, [67]). Several cancer cell lines express PDGFs and
PDGFRs [68]. Autocrine signaling loops have been discovered in transformed cells [69,
70].
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In addition, abnormal tumor stromal interactions have been implicated in the
development of breast cancer ([71] as reviewed in [72]). Of note, PDGFs have been
implicated in the desmoplastic response seen in some breast cancers [73, 74].

In

addition, PDGF Receptor expression has been detected in a number of soft tissue tumors
further implicating aberrant PDGF signaling in abnormal tumor growth [75]. Despite
multiple reports of PDGF receptor expression in breast cancer [76-78], the PDGF ligand
in breast cancer had yet to be determined.
This is of importance as aberrant PDGF signaling can be targeted with
pharmacologic therapies. Currently there are several drugs approved by the United States
Food and Drug Administration (FDA) which target aberrant PDGFR signaling ([79], as
reviewed in [80]). Imatinib mesylate (Gleevec , STI571, Novartis) is the most notable
of these drugs and the first drug created utilizing rational drug design [81, 82]. Dasatinib
(Sprycel , BMS-354825, Bristol-Myers Squibb), sunitinib malate (Sutent , SU11248,
Pfizer), sorafenib (Nexavar®, Bayer and Onyx Pharmaceuticals) are other receptor
tyrosine kinase inhibitors that target PDGFRs.
PDGF C & Breast Cancer
PDGF C and PDGF D are the newest members of the platelet-derived growth
factor (PDGF) family [68, 83, 84]. PDGF C was identified in the year 2000 by three
groups who designated it “fallotein” [85], “Spinal Cord-Derived Growth Factor
(SCDGF)” [86], and finally “PDGF C” [87]. The PDGF C gene is located on
chromosome 4q32 and consists of six exons [68, 88]. PDGF C mRNA expression was

9

analyzed in a myriad of human tissues and found to be highly expressed in heart,
pancreas, kidney, liver and ovary human tissues with intermediate or no expression in
several other human tissues analyzed [87]. Of note, this study did not analyze expression
in human breast tissue [87]. A majority of the mRNA was of approximately 3.9kilobases while there was a minor transcript of approximately 2.8-kilobases detected in
human tissues [87].
PDGF C and PDGF D are unique from PDGF A and PDGF B in that they contain
an amino-terminal CUB domain encoded by exons 2 and 3 [68, 87] which has been
suggested to bind the pericellular matrix and block receptor binding [89]. Like the other
members of the PDGF family, the carboxy-terminus of PDGF C contains the conserved
cysteine knot growth factor homology domain [68]. PDGF C has 12 cysteine residues
which form three intra-subunit disulfide bonds and two inter-subunit disulfide bonds [89].
PDGF C forms homodimers, and latent homodimers are secreted then requiring removal
of the CUB domain in order to activate the PDGF receptor [87]. The growth factor
domain of PDGF C stimulates receptor phosphorylation while full-length PDGF C does
not [87]. The serine protease tissue plasminogen activator (tPA) is capable of
proteolytically activating PDGF C by removal of the CUB domain, necessary for PDGFR
activation [90, 91]. When secreted and proteolytically activated, PDGF C homodimers
bind to and activate platelet-derived growth factor receptor alpha homodimers (PDGFRα/α) [87, 92] or platelet-derived growth factor receptor-alpha/beta (PDGFR-α/β)
heterodimers (Figure 1) [92-94]. PDGF D activates PDGFR-β receptors and when
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present with PDGFR-β, PDGFR-α receptors are also activated likely by
heterodimerization of the alpha and beta receptors [84] .
Since its discovery, PDGF C has been implicated in normal development and in
many disease processes. Studies have shown that PDGF C plays an important role in
palate formation [95], and also in the aberrant development in cleft lip/cleft palate (CL/P)
[96]. In addition PDGF C is necessary for normal kidney development and likewise
aberrant PDGDC signaling has been implicated in the development of glomerular
diseases [97].
Several studies have implicated PDGF C in the development of fibrosis [98].
Aberrant expression of PDGF C in the heart of a transgenic mouse model resulted in
cardiac fibrosis along with heart and vascular dysfunction [99]. An increase in PDGF C
expression was seen in a strain of mice that suffer from bleomycin-induced lung fibrosis,
while there was no increase in PDGF C expression in a bleomycin-resistant mouse strain
[100]. Their results suggest that PDGF C expression plays a role in lung fibrosis.
Furthermore, Interleukin-13 (IL-13) was shown to stimulate lung fibroblasts via PDGF
signaling [101]. Later it was shown that IL-13 transgenic mice demonstrate increased
PDGF C expression in the lungs suggesting PDGF C’s role in lung disease and fibrosis
[102]. In addition, showing a continuum of aberrant signaling in the liver, PDGF C
causes liver fibrosis and later carcinoma development [103].
PDGF C’s specific role in tumorigenesis was first demonstrated in 2001 when it
was shown that the aberrant transcription factor in Ewing Family Tumors (EFTs)
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increased PDGF C expression [104]. In addition it was demonstrated that NIH/3T3 cells
could be transformed by expression of PDGF C, and that several Ewing Family Tumor
cell lines and primary tumor samples expressed PDGF C [104]. Inhibition of PDGF C
signaling was able to reverse the malignant phenotype, as demonstrated by anchorageindependent growth, and thus has been suggested as a potential therapeutic target in these
tumors [105]. Later, PDGFR-α was demonstrated in medulloblastoma tumors [106].
Discovery of expression of PDGF C and activated PDGFR-α in medulloblastoma cell
lines suggested the possibility of autocrine signaling being important in these tumors
[106]. Further evidence of PDGF C functioning in an autocrine manner as a growth
factor in cancer was demonstrated in glioblastoma brain tumor cells [107]. PDGF C has
been shown to also signal in a paracrine manner within the tumor microenvironment
causing blood vessel maturation and stromal cell recruitment [108, 109]. Expression of
PDGF C in the liver of mice produced severe hepatic fibrosis which progressed to liver
adenomas and finally lead to the development of hepatocellular carcinoma [103].
Increasing evidence in the literature has implicated aberrant PDGF signaling in
breast cancer development and metastases [75-78, 110-113]. Thus our laboratory set out
to determine the PDGF ligand most relevant in breast cancer. Utilizing Gene-expression
Based Outcome for Breast Cancer Online (GOBO) Gene Set Expression (GSE) analysis
[2] to assess gene expression in 51 human breast cancer cell lines [1] shows interesting
results. GOBO analyzes gene expression data in these human breast cancer cell lines
grouped into breast cancer transcription profile subgroups Basal A, Basal B and Luminal,
as defined in the literature [1]. A subset of 30 breast cancer cell lines- 16 Luminal, 4
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Basal A, and 10 Basal B breast cancer cell lines- were tested for invasive potential in
vitro, and it was found that Basal B cell lines were more often highly invasive cell lines
as compared to Luminal or Basal A breast cancer cell lines [1]. Furthermore, the Basal B
cell lines tended to appear more mesenchymal, less differentiated and Basal B cells also
showed expression of the CD44+/CD24–/low pattern associated with breast cancer stem
cells [1, 114, 115]. Total PDGF C expression is shown to be highest in Basal B breast
cancer cell lines, and is also high in Basal A human breast cancer cell lines while it is
comparatively lower in Luminal breast cancer cell lines (Figure 2A). The difference in
PDGF C expression is significant amongst the three breast cancer cell line subtypes,
p≤0.00001 (Figure 2A.)
As shown in Figure 2B, the relative expression of overall PDGF C varies widely
in the panel of 51 human breast cancer cell lines, with the highest PDGF C expression
being found in the MDA-MB-231 cell line. Such gene expression data in a large panel of
human breast cancer cell lines helps identify which cell lines would be ideally suited for
further in vitro and in vivo studies.
In addition, GOBO analysis groups and analyzes the breast cancer cell lines
according to the clinical features assessed in breast cancers, such as hormone receptor
expression and HER2/neu overexpression (Figure 3). According to GOBO analysis,
PDGF C expression varies significantly amongst the clinical subtypes of breast cancer
cell lines (Figure 3C). There is no significant difference amongst the various clinical
subtypes of breast cancer cell lines in expression of PDGF A, PDGF D, or either of the
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Figure 2. Gene set analysis in breast cancer cell lines for PDGF C expression. A) Box
plots from Gene Expression-based Outcome for Breast Cancer Online (GOBO) of
PDGF C expression in cell lines grouped into Basal A (red), Basal B (grey), and
Luminal (blue) subgroups as described in Neve et al 2006 [1] and Ringner et al 2011
[2]) B) Gene Expression-based Outcome for Breast Cancer Online (GOBO) data
output for relative (total) PDGF C expression in a panel of 51 breast cancer cell lines,
color coded into Basal A (red), Basal B (grey), and Luminal (blue) subgroups. Based
on data from Neve et al 2006 [1] and figures generated by GOBO Ringner et al 2011
[2]. http://co.bmc.lu.se/gobo
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PDGF receptors (Figure 3A, D, E, & F). Interestingly, there is a significant difference in
PDGF B expression amongst the clinical subtypes of breast cancer cell lines with the
highest PDGF B expression being in hormone-receptor positive and HER2/neu
overexpressing breast cancer cell lines, as compared to significantly lower PDGF B
expression in the triple-negative breast cancer cell lines (p= 0.01398, Figure 3B). Most
interesting, PDGF C expression is highest amongst the triple-negative (TN) breast cancer
cell lines, and then second highest amongst the HER2/neu overexpressing (HER2) cell
lines, with the lowest expression of PDGF C seen in the hormone receptor-positive (HR)
breast cancer cell lines (p= 0.00031, Figure 3C). Taken together, this suggests that
PDGF C expression tends to be higher in breast cancer cell lines with poor prognostic
features such as triple-negative or HER2/neu expressing breast cancer.
Our laboratory screened a panel of human breast cancer cell lines and found that
PDGF C expression appeared to increase in more aggressive breast cancer cell lines such
as MDA-MB-231 cells, BT-549 cells and the SUM cell lines (Figure 4, data courtesy of
NJH). Furthermore, a splice variant of PDGF C was discovered that is designated
truncated PDGF C (Figure 4, data courtesy of NJH). Approximately 40 – 60% of genes
have alternatively spliced forms [116]. With only approximately 30,000 genes in the
human genome, alternative splicing is important for genetic diversity. Alternative
splicing of a transcript can be the result of exon inclusion or exclusion, a new 5’ site or a
new 3’ site which can produce an alternative amino-terminus translation initiation site,
frameshift truncation or extension of the carboxy-terminus, or an in-frame insertion or
deletion within the protein [116]. The PDGF C gene has two mRNA isoforms, full-
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Figure 3. Gene set analysis in breast cancer cell lines for the PDGF family. Box plots
from GOBO depicting A) PDGF A B) PDGF B C) PDGF C D) PDGF D E) PDGFRA
F) PDGFRB gene expression in 51 breast cancer cell lines grouped into clinical
subtypes: triple-negative (TN, red), HER2-positive (HER2, purple), and hormone
receptor-positive (HR, blue). Based on data from Neve et al 2006 [1] and figures
generated by GOBO Ringner et al 2011 [2] http://co.bmc.lu.se/gobo
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Figure 4. PDGF family mRNA expression in human breast cancer cell lines and
identification of a PDGF C splice variant. RT-PCR analysis of PDGF A, B, C and D
in MCF-10A, MCF-7, T47D, BT-549, MDA-MB-231, SUM102, SUM149, and
SUM190 cell lines. Data Courtesy of Dr. Newton J. Hurst, Jr, MD, PhD. HR=
Hormone receptor positive, TN= Triple-Negative, HER2= HER2/neu overexpressing.
length PDGF C (FL-PDGF C) and the more recently discovered truncated PDGF C (tPDGF C). The truncated PDGF C isoform is generated due to retention of a 61 base pair
exon resulting in an amino-terminally truncated isoform of PDGF C (Figure 5). This
PDGF C splice variant has been demonstrated in fetal brain [117] and in breast cancer
cell lines (our laboratory’s unpublished data, Figure 4, data courtesy of NJH).
Full-length PDGF C is 345 amino acids long. The expected molecular weight of
this protein based on the number of amino acids would be approximately 38 kDa [118],
while calculating based on the amino acid sequence estimates its size as 39 kDa [119]. A
putative signal-peptidase cleavage site is located between amino acids 22 and 23 of
PDGF C [87]. After removal of the signal sequence the expected molecular weight of
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Figure 5. A diagram for the PDGF C mRNA and the protein domain structure. PDGF
C gene diagram depicting exon locations (numbers), the translation initiation sites for
FL-PDGF C (red arrow) and t-PDGF C (blue arrow).
full-length PDGF C is ~37 kDa [87]. The truncated form of PDGF C is predicted to be
182 amino acids in length and would be expected to be 20 kDa based on simple amino
acid length [118] while based on the actual amino acid sequence is would be expected to
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be 21 kDa in size [119]. In addition, the sequence of PDGF C contains three presumed Nglycosylation sites at amino acids 25, 55, and 254 [87] and treatment with glycosidase
has been shown to alter the molecular weight of PDGF C [88]. In addition, SUMOylated
PDGF C has been demonstrated in human thyroid tissue, papillary thyroid carcinomas
and various cell lines [120]. In these tissues and cell lines PDGF C of various molecular
weights was demonstrated. The ~55 kDa form appeared to be the SUMOylated form,
while the ~39 kDa and ~43 kDa forms were not [120]. While a full-length PDGF C ~45
kDa species appears to be glycosylated in COS-1 cells and two species ~25 kDa and ~20
kDa are CUB domain-containing PDGF C entities [88]. Under non-reducing conditions
medulloblastoma cells showed PDGF C entities at 80 kDa and 100 kDa that were 55 kDa
under reduced conditions [106]. Thus, the molecular weight of PDGF C depends on the
isoform, post-translational modifications and ligand dimerization.
Although the gene expression data of the GOBO tool does not distinguish
between the expression of the PDGF C mRNA splice variants, this online tool still
provides valuable data about total PDGF C expression in a large panel of human breast
cancer cell lines. Correlating well with our laboratory’s semi-quantitative PCR data
(Figure 4, data courtesy of NJH), GOBO data output also shows relatively high level of
total PDGF C expression in human breast cancer cell lines such as MDA-MB-231 and
BT-549, while there is very low total PDGF C expression in the hormone receptor
positive human breast cancer cell line MCF-7 (Figure 2B). Corroborating the GOBO
data showing that PDGF C expression varies significantly amongst the clinical subtypes
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of cell lines (Figure 3C), our laboratory finds that PDGF C expression appears to increase
in breast cancer cell lines with poor prognostic features (Figure 4, data courtesy of NJH).
In addition to the recent discovery of a PDGF C splice variant, PDGF C has been
recently reported to have nuclear localization. This was reported in the literature in 2006
when Reigstad, et al described nuclear localization of PDGF C in human papillary
thyroid carcinoma samples and normal thyroid tissue samples from 14 patients by
immunohistochemical (IHC) staining [120]. In addition, that study showed that several
cultured cell lines also displayed nuclear localization of PDGF C and that inhibition of
PI3K with Wortmannin treatment reduced PDGF C nuclear staining by indirect
immunofluorescence in cell culture. Actinomycin-D treatment, serum starvation, and
confluent cell cultures also acted to reduce the amount of nuclear PDGF C in cultured
cells in their study. They also demonstrate that structural modeling indicates a potential
nuclear localization sequence in the growth factor domain of PDGF C amino acids 312 –
322 with a putative SUMOlyation site on positively charged
the outer surface of the protein [120].

314

lysine believed to be at
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Statement of Hypotheses & Goals of this study
To determine the role of PDGF C and its splice variant in Breast Cancer:
•

Analyze the expression of PDGF C isoforms in breast cancer cell lines

•

Analyze the effect of alteration of PDGF C isoform expression on the behavior of

breast cancer cells in vitro & in vivo

We hypothesize that in breast cancer cells:
•

PDGF C expression increases the aggressiveness

•

t-PDGF C expression modulates the function of FL-PDGF C

Aim 1: To establish the significance of PDGF C expression on the malignant
characteristics of breast carcinoma cells.

Aim 2: To investigate t-PDGF C regulation of FL-PDGF C stability and subcellular
localization in human breast carcinoma cells.

Aim 3: To elucidate the role of PDGF C isoforms in breast cancer progression in vivo.
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CHAPTER 2
MATERIALS & METHODS
Cell culture
MCF-7, BT-549, and resulting transfectant cells were maintained in DMEM/F-12 (1:1)
media (Gibco catalog # 11320), supplemented with 10% FBS (Gibco catalog # 16000)
and 1% Pen/Strep (Hyclone

10,000 U/mL of Pen, 10,000 U/mL of Strep; Thermo

Scientific catalog # SV30010). T47D and resulting transfectant cells were maintained in
DMEM/F-12 (1:1) media (catalog # 11320), supplemented with 10% FBS (Gibco catalog
# 16000), 1% Pen/Strep (Hyclone

10,000 U/mL of Pen, 10,000 U/mL of Strep; Thermo

Scientific catalog # SV30010), 1% Glutamine (200 mM; Cellgro Cat No 25-005-CI), 1
mL fungizone (250 µg/mL; Gibco 15290-018), and 0.55 mL insulin (10 mg/mL; Sigma
catalog # I0516-5mL). MDA-MB-231 cells, COS-1 cells and resulting transfectant cells
were maintained in DMEM High Glucose media (Gibco catalog # 11995), supplemented
with 10% FBS (Gibco catalog # 16000), and 1% Pen/Strep (Hyclone

10,000 U/mL of

Pen, 10,000 U/mL of Strep; Thermo Scientific catalog # SV30010).
Cell counting
To count cells using the Reichert Bright Line

Hemacytometer 0.1 mm deep, cells are

washed once with Phosphate Buffered Saline (PBS) and trypsanized, then spun down and
resuspended in media. The cell suspension is diluted 1:10 in media (10 µL of cell
suspension + 90 µL of media). To this 20 µL of 0.4% Trypan Blue Solution (Sigma
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T8154) is added (a 1.2 dilution) and mixed by pipetting. To count cells, 10 µL of the
cell/trypan blue solution is pipetted into the hemocytometer/coverslip. The bright cells
(live cells) in all four 1.00 sq mm corner quadrants of the hemacytometer are counted.
The number of cells per milliliter is calculated using the following formula:
Number of cells/mL = total number cells in all four corner quadrants /4 * 1.2* 10* 104
Cell lines

Table 1. Human Breast Cancer Cell Line Characteristics. [1, 121, 122]
Origin:
1°
Tumor?

Origin:
Metastatic
Site?

ER

PR

HER2

1° tumor
histology

MCF-7

N

Y, PE

+

+

–

IDC

T47D

N

Y, PE

+

+

–

IDC

BT-549

Y

N

–

–

–

IDC

MDAMB-231

N

Y, PE

–

–

–

IDC

SUM102PT

Y

N

–

–

–

IDC

SUM149PT

Y

N

–

–

–

Inflammatory

SUM190PT

Y

N

–

–

+

Inflammatory

ER = estrogen receptor, PR = progesterone receptor, + indicates expression of
receptor, – indicates lack of receptor expression. HER2 = HER2/neu, + indicates
overexpression of HER2/neu. Y = yes, N = no. PE = pulmonary effusion. IDC =
invasive ductal carcinoma.
MCF-10A cells are a spontaneously immortalized non-tumorigenic breast epithelial cell
line isolated from a 36-year-old woman with fibrocystic disease of the breast [123, 124].
MCF-7 cells are hormone receptor positive human breast cancer cells isolated from the
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metastatic pleural effusion of a patient [125, 126]. BT-549 cells are a hormone receptor
negative cell line isolated from a primary breast cancer [1]. MDA-MB-231 breast cancer
cell line was established from the pleural effusion of a 51-year-old woman with a poorly
differentiated breast cancer [127]. T47D is a hormone receptor positive breast cancer cell
line isolated from a 54-year-old patient with breast cancer [128]. SUM102, SUM149,
SUM190 are human breast cancer cell lines [1, 121, 122]. COS-1 cells are a simian cell
line [129].
Transfection
Cells were transfected using Lipofectamine™ 2000 Transfection Reagent (Invitrogen
Cat. No. 11668-019) according to the manufacturer’s protocol. For transient trasfection,
following transfection cells were grown overnight in normal serum-containing growth
media and the following day cells were serum-starved for 48-hours before collecting
RNA or protein. For stable transfection, cells were kept under antibiotic selection for 2weeks. Proper expression was confirmed by PCR and then liquid nitrogen stocks were
made.
Vaccinia virus infection transfection
MCF-7 cells were infected with vaccinia virus. After 30 minutes, the cells were washed
with PBS and transfected with plasmid using Effectene reagent (Qiagen, Valencia, CA).
After 48 hours of co-infection/transfection with vaccinia virus and expression plasmid,
the serum-free conditioned medium and cellular fractionation protein was collected.
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In vitro cleavage by recombinant human matriptase
Microcon® centrifugal filter devices were used to exchange the conditioned media in the
sample buffer with rhMatriptase buffer (50 mM Tris, 50 mM NaCl, 0.01% (v/v) Tween®
20, pH 9.0). Recombinant Human Matriptase/ST14 Catalytic Domain (rhMatriptase)
(R&D Systems, Catalog # 3946-SE) was diluted 1:10 in PBS and 6 µL of the diluted
rhMatriptase was added to 20 µL of concentrated conditioned media. Samples were then
incubated at 37°C for the times indicated. Samples were resolved by SDS-PAGE and
Western blot for analysis of proteolysis.
Plasmid DNA preparation
Invitrogen™ Subcloning Efficiency™ DH5α™ Competent Cell (Cat. No. 18265-017)
were transformed with plasmid according to the manufacturers protocol. Transformed
cells were spread on Invitrogen™ imMedia™ Amp Agar plates (Cat. No. Q601-20) and
grown overnight at 37 °C. Isolated colonies were picked and grown up overnight at 37°C
with shaking 225 rpm in LB broth (Sigma Cat. No. L3022) supplemented with the
appropriate selective antibiotic. Maxi prep kit (Qiagen HiSpeed® Plasmid kit, Cat. No.
12663) or QIAprep

Miniprep kit (Qiagen, Cat No. 27106) was used to isolate plasmid

DNA. This DNA was used for transfections of cell lines in cell culture.
Mutagenesis
10 nanograms of template were used for the mutagenesis reactions using the QuikChange
II Site-Directed Mutagenesis Kit (Agilent Technologies, catalog #200524).

The
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mutagenesis reaction was incubated at 95°C for 30 seconds and then run for 18 cycles,
each cycle consisting of: 30 seconds at 95°C, 1 minute at 55°C and 7 minutes at 68°C.

Table 2. Mutagenesis Primers.
PDGF C NLS 5’RKRK/AAAA
CCTTCAGTTGGCACCAGCGACCGGTGTCGCGGGATTGCACG
Forward
CATCACTCACC -3’
PDGF C NLS 5’RKRK/AAAA
GGTGAGTGATGCGTGCAATCCCGCGACACCGGTCGCTGGTG
Reverse
CCAACTGAAGG -3’
PDGF
∆Signal
Sequence
Forward

C 5’GCTGGCTAGCGTTTAAACTTAAGATGGAATCCAACCTGAGT
AG -3’

PDGF
C 5’∆Signal
CTACTCAGGTTGGATTCCATCTTAAGTTTAAACGCTAGCCAG
Sequence
C -3’
Reverse
Then mutagenesis reactions were transformed into XL1-Blue supercompetent cells
according to the manufacturer’s protocol, then grown for 1 hour at 37°C in SOC media
and finally spread on LB-ampicillin agar plates incubated overnight at 37°C. To make
agar plates a 2X agar solution (3 grams of Bacto™ Agar, BD Bioscience REF 214010, in
100 mLs of dH2O makes a 2X solution), mixed with Invitrogen imMedia™ Amp Blue
(Part No. 45-0038) 1 packet in 100 mLs of dH2O gives a 2X solution of the liquid media,
to give a 1X Blue/White agar screening solution and was then poured out into plates.
These Blue/White screening plates were used to grow the transformation control
reactions, the mutagenesis control reactions, and mutagenesis reactions. Plasmid DNA
was isolated as described previously. Mutation was confirmed by sequencing of the
plasmid DNA.
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Sequencing of mutagenesis constructs
Constructs were sent out for sequencing using GENEWIZ Molecular Biology.

Table 3. PDGF C Sequencing Primers.
“C Seq 1R”

5’- GTATGAGGAAACCTTGGGCTG -3’

“C Seq 2F”

5’- CTGGTGTGGTTCTGGTACTG -3’

“C Seq 3R”

5’- GTCTTCCAAGGTACTAAAGGCAG -3’

“C Seq 4F”

5’- TGCACACCTCGTAACTTCTC -3’

GENEWIZ standard T7 promoter Primer and BGH Primer where used to sequence the
beginning and the end of the sequence since pcDNA3.1 vectors contain those primer
annealing sequences.
Conditioned media
A 100 mm dish of cells were grown under normal serum-containing conditions until
confluent. The media was aspirated, and then the cells were washed twice with PBS and
replaced with 5 mLs of serum-free media. Cells were kept at 37°C 5% CO2 for 48 hours
under these conditions. Media was collected and spun at 2000 rpm @ 4°C for 5 minutes
to pellet any cells/cellular debris. To concentrate the conditioned media was transferred
to Amicon® Ultra-4 Centrifugal Filter Units (Millipore UFC801024), spun at 4000 rpm
at 4°C for 20 minutes. The flow-through was discarded and phenol red was exchanged
out by washing with PBS, spinning at 4000 rpm at 4°C for 20 minutes and discarding the
flow-through. Washing with PBS was repeated two more times to remove all residual
phenol-red. Protein level of concentrated conditioned media was determined using the
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Pierce BCA assay as detailed below using PBS as the blank. Dr. Julie Boerner kindly
provided conditioned media from SUM102, and SUM149 cell lines.
Proliferation assay
Cells were seeded into 96-well tissue culture plates in the appropriate cell culture media.
For serum-containing conditions (10% serum) and low serum conditions (1% serum),
1,000 cells were seeded per well. After the indicated incubation times, WST-1 reagent
(Roche Cat No. 1 644 807) was added to each well according to the manufacturer’s
protocol. The absorbance at 450 nm was read by microplate reader (Bio-Rad Microplate
Reader, Model No. Benchmark) and adjusted using cell-free media as the blank. Samples
were done in six replicates.
Invasion assay
Growth Factor-Reduced Matrigel™ coated transwells (BD Biocoat™ 24 well plate, 0.8
micron, Product Number 354483) were rehydrated with serum-free media. Cells were
seeded at 5x104 cells/mL in serum free media. Chemoattractant (500 µL of serum
containing media) was added to the bottom chamber of the invasion assay. The rehydrated transwell was placed over the chemoattractant and 500 µL of cells (5x104
cells/mL) were added to the top chamber.

Cells were allowed to migrate while

incubating in humidified 37°C, 5% CO2 atmosphere. Matrigel™ and non-invading cells
were scrubbed from the inside of the invasion chambers with moistened cotton swabs.
Invading cells were stained with crystal violet and visualized under the microscope and
counted.

28

Soft agar assay
BactoAgar (BD catalog # 214050) combined with the cells’ normal growth media (1:1)
was used to make a bottom layer of 0.6% agar, and a top layer of 1.2% agar. The top
layer also contained 5,000 cells/mL. These were grown in 6-well plates with 2 mL of
normal growth media per well. The media was changed every third day. Colonies were
analyzed using the colony counter (Oxford Optronix) in the Translational Research Core
of the Karmanos Cancer Institute. Utilizing the strictest of parameters looking at the
shape of a colony as well as its relative tightness may have led to dismissal of colonies
visually observed rather than inclusion. Samples were done in triplicates.
Lysis and RNA isolation
RNA was isolated with the RNeasy

Mini Kit (Qiagen, Cat. No. 74106) according the

manufacturer’s protocol.
Reverse transcription
The iScript cDNA Synthesis Kit (BioRad, Catalog #170-8891) was used for reverse
transcription using 1 µg of RNA and the reaction protocol of 5 minutes at 25°C, 30
minutes at 42°C, 5 minutes at 85°C, then hold at 4°C to create cDNA. Samples of cDNA
from several human breast cancer cell lines were a gift from former Kim Laboratory
member, Dr. Newton J. Hurst, Jr., MD, PhD. This cDNA was used to assess PDGF C
levels by Real Time PCR.
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Semi-quantitative RT-PCR
Table 4. Human Semi-Quantitative PCR Primers.
Target
Sequence
PDGF A
Forward:
5’- TGAGGATTCTTTGGACACCA -3’
Reverse:
5’- GGGCCAGATCAGGAAGTTG -3’
PDGF B
Forward:
5’- CATTCCCGAGGAGCTTTATG -3’
Reverse:
5’- CTCAGCAATGGTCAGGGAAC -3’
PDGF C
Forward:
5’- TCCAGCAACAAGGAACAGAA -3’
Reverse:
5’- GGGTCTTCAAGCCCAAATCT -3’
PDGF D
Forward:
5’- GAACAGCTACCCCAGGAACC -3’
Reverse:
5’- CTTGTGTCCACACCATCGTC -3’
PDGFR-α
Forward:
5’- GAACTCACGGTGGCTGCTG -3’
Reverse:
5’- ACTTTCATGACAGGTTGGG -3’
PDGFR-β
Forward:
5’- TTTTGCACCCACAATGACTC -3’
Reverse:
5’- CCAATGGTGGTTTTGCAGAT -3’
GAPDH
Forward:
5’- ATCACCATCTTCCAGGAGCGA -3’
Reverse:
5’- GCCAGTGAGCTTCCCGTTCA -3’
The GoTaq

Flexi DNA Polymerase kit (Promega, catalog #M8291) was used for semi-

quantitative RT-PCR using 1 µL of reverse transcription reaction. Cycling parameters
were 95°C for 2 minutes, then 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds,
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72°C for 2 minutes 30 seconds. Then at the end there is one 72°C step for 5 minutes
followed by holding at 4°C. PCR reactions were separated and visualized on agarose
gels with ethidium bromide with an UV transilluminator. Samples were run alongside
DNA size standards (Invitrogen TrackIt™ 1 kb Plus DNA ladder, catalog #10488-085) to
verify size.
Real Time PCR
Table 5. Real Time PCR Primers.
Target

Sequence

Total PDGF C

Forward: 5’-AACGCTGTGGTGGGAACTGTGC-3’
Reverse: 5’-TGCAATCCCCTGACACCGGTCT-3’
Forward: 5’-TCCAAGCATCTGGACTGGCATAGA-3’

t-PDGF C

Reverse: 5’-AGTATGAGGAAACCTTGGGCTGTGA-3’
Forward: 5’-ATCACCATCTTCCAGGAGCGA-3’

GAPDH

Reverse: 5’-GCCAGTGAGCTTCCCGTTCA-3’

Reverse transcription reaction was prepared and mixed with primers according to the
Stratagene Brilliant SYBR

Green QPCR Master Mix (Catalog# 600548). Samples

were run on the Eppendorf Realplex2 Mastercycler epgradient machine. Cycling
parameters were 10 minutes at 95°C, then 40 cycles of 30 seconds at 95°C, 1 minute at
55°C and 1 minute at 72°C. Samples were run in triplicate. Differences in RNA levels
were calculated by the

CT method and error bars were calculated by propagation of

error from the replicate samples as described elsewhere [130, 131].
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Protein extraction
Cell cultures were washed twice with PBS and then whole cell lysate was isolated by
adding 1x RIPA buffer (Millipore RIPA lysis buffer 10x product # 20-188 diluted to 1X
with dH2O) including freshly added protease inhibitors (Roche cOmplete, EDTA-free
Protease

Inhibitor

Cocktail

Tablets,

Product

Number

11873580001;

Phenylmethanesulfonyl fluoride, PMSF) and phosphatase inhibitors (Sodium Fluoride,
Sodium Orthovanadate) to cells and scraping with a rubber policeman. The lysate was
transferred to tubes and incubated on ice for 30 minutes. Samples were then centrifuged
at 4°C at 12,000 rpm for 20 minutes. The supernatant, the whole cell lysate, was
transferred to new tubes and saved for analysis.
Nuclear and cytosolic fractionation
Cells are rinsed twice with PBS and then cell lysis buffer (10 mM HEPES pH 7.8, 10
mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.3% NP-40, 1x Roche cOmplete, EDTA-free
Protease Inhibitor Cocktail, 1 mM DTT, 0.5 mM PMSF) was added to the tissue culture
dish. The tissue culture plates are incubated on ice for approximately 10 minutes. The
cells are then scraped with a rubber policeman and samples were transferred to tubes.
The tubes were incubated on ice for 10 minutes. The tubes were spun at high speed for
two minutes at 4°C. The supernatant, the cytoplasmic fraction, was transferred to new
tubes and the protein quantitated. To extract the nuclear fraction the remaining pellet was
washed with cold PBS and then spun at full speed for two minutes at 4°C.

The

supernatant PBS was discarded. Nuclear extraction buffer (20 mM HEPES pH 7.9, 400
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mM NaCl, 1 mM EDTA, 1 mM EGTA, 1x Roche cOmplete, EDTA-free Protease
Inhibitor Cocktail, 1 mM DTT and 1 mM PMSF) was added to the pellet and incubated
on ice for 30 minutes with intermittent vortexing to mix. The tubes were then spun at
maximum speed for 10 minutes at 4°C. The supernatant, the nuclear fraction, was
transferred to new tubes and the protein quantitated.
Subcellular fractionation
Subcellular fractions: cytoplasmic extract, membrane extract, soluble nuclear extract,
chromatin-bound extract and cytoskeletal extract were isolated using the Subcellular
Protein Fractionation Kit for Cultured Cells (Thermo Scientific Product Number 78840)
according to the manufacturer’s protocol.
Protein quantitation
Quantifying the amount of protein in whole cell lysates, nuclear or cytosolic
fractionations, or subcellular fractions was done using the Thermo Scientific Pierce BCA
(bicinchoninic acid) Protein Assay kit (Product Number 23225) using Thermo Scientific
Pierce Bovine Serum Albumin (BSA) Standards.
Western blotting
Protein was separated on custom made Tris-Glycine Sodium Dodecyl Sulfate (SDS)
Polyacrylamide gels (PAGE). Protein was transferred to Whatman

Optitran

BA-S83

0.2 µm pore size reinforced nitrocellulose membranes (REF 10439396), blocked in 5%
milk in Tris Buffered Saline with Tween

20 (TBST: 50 mM Tris Base, 150 mM sodium
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chloride, 0.2 % Tween

20) and incubated in primary antibody 5% milk in TBST. Blots

were washed and incubated in the appropriate secondary antibody and then washed three
times with TBST and incubated with Western Lightning® Plus-ECL, Enhanced
Chemiluminescence Substrate (Perkin Elmer Product No. NEL103001) and then
developed to Hyblot CL

Autoradiography film (Denville Scientific, Inc., Cat No

E3012).
Primary antibodies
PDGF C (R&D Systems, product number AF1560), GAPDH (Santa Cruz, product
number sc-25778), Phospho-Erk (Thr202/204) (Cell signaling, product number 9101),
Total Erk (Cell signaling, product number 9102), Phospho-Akt (Ser473) (Cell Signaling,
product number 9271), Total Akt (Cell Signaling, product number 9272), Histone H1 +
core proteins (Millipore, product number MAB052), SP1 (Cell Signaling, product
number 5931), Cytokeratin 18 (Millipore product number CBL 185), Hsp90 (Santa Cruz,
product number sc-13119), Transferrin Receptor (BD Transduction, product number
612124), Myc-Tag (Cell Signaling, product number 2276) antibodies were used
according to manufacturers’ protocol.
Secondary antibodies
Goat anti-Rabbit peroxidase conjugated secondary antibody (Jackson ImmunoResearch,
product 111-035-003) was diluted 1:5000. Rabbit anti-Mouse peroxidase conjugated
secondary antibody (Sigma, product A9044) was diluted 1:5000. Donkey anti-Goat
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peroxidase conjugated secondary antibody (R&D Systems, product HAF109) was diluted
1:1000.
PDGF C custom antibody
A custom antibody against the growth factor domain of PDGF C (amino acids 230-250)
was created using a peptide (N’-CGRKSRVVDLNLLTEEVRLYSC-C’). The resultant
antibody was affinity purified (Zymed Biomedical, San Francisco, CA, USA) as
described previously [132].
Antibody specificity test
40 µL of conditioned media or 40 µg of whole cell lysate from stably transfected MCF-7
cells was run under reducing conditions. The resulting western blots were cut into slices.
A custom peptide Hs PDGF C #230-250 peptide (Zymed

Laboratories, Inc, South San

Francisco, CA) used to generate a custom PDGF C antibody was diluted in solution with
1:1000 PDGF C custom antibody in 5% milk in TBST and the preservative sodium azide.
Peptide:Antibody ratios of 2:1, 10:1 and 50:1 molar competition (peptide to antibody
ratio) were prepared. Peptide was pre-incubated with the custom antibody 1 hour at 4°C.
Western blot membranes of control transfected MCF-7 Neo cell line conditioned media
which have undetectable levels of PDGF C, and PDGF C overexpressing transfected
MCF-7 cell line conditioned media which have very high levels of PDGF C, were
blocked for 1 hour at room temperature in 5% milk in TBST and then incubated with
antibody alone or peptide:antibody solutions at 4°C overnight, then developed to film.
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Cell culture protease inhibition experiments
Cells were washed twice with PBS and serum free media was added containing the
appropriate concentration of protease inhibitors. Cells were incubated for 48 hours under
otherwise normal culture conditions. Protease Inhibitor Cocktail was used in a 1:200
dilution according to manufacturers specifications (Sigma, product number P1860).
Aprotinin was used at 10 µg/mL (Sigma, product number A3428), and AEBSF was used
at 0.25 mM concentration (Sigma, product number A8456) in serum free cell culture
media for protease inhibition experiments.
Animal studies
NOD/SCID Mouse
An animal model is necessary to simulate all the steps of tumor metastasis: intravasation,
survival in the blood and lymphatics, extravasation, and colonization in a new organ. No
in vitro model can simulate all of these sequential steps necessary for tumor metastasis.
Immunodeficient animal models allow implanted human tumor cell growth. There are
various immunodeficient animal models available including the nude mouse [133], SCID
mouse [134, 135], NOD/SCID mouse [136] and Rag-1-deficient mouse [137].
NOD/SCID mice stand out as particularly well suited to study primary tumor growth and
tumor metastatic spread [138].
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Tumor measurements
1x106 cells in 50 µl of Matrigel™ (BD Biosciences):media (1:1) mixture were injected
into the R4 mammary fat pad of 6-week old female NOD/SCID mice with a 25 gauge
needle by Dr. Fred Miller (Karmanos Cancer Institute). Tumor measurements were taken
at least weekly using digital calipers. Tumor volumes were calculated as described
elsewhere using the formula tumor volume = a x b2/2, where b is the smaller of the two
measured tumor diameters [139, 140].

Miss Lisa Movilla helped with the animal

handling.
Tail vein injection
MDA-MB-231 cells (1x106 cells in 100 µL of sterile PBS) were injected in the tail vein
of CB17 SCID mice using a 27-gauge needle by Dr. Fred Miller (Karmanos Cancer
Institute).

Eight mice were injected with MDA-MB-231 shScramble, 8 mice were

injected with MDA-MB-231 shPDGF C and three mice were left uninjected. Mice were
monitored weekly and euthanized if in apparent distress. Shortly after injection one
mouse from the MDA-MB-231 shScramble injected group died and two mice from the
MDA-MB-231 shPDGF C injected group died. On day 30 after injection, one mouse
from the MDA-MB-231 shScramble group was euthanized for apparent respiratory
distress. On Day 32 all remaining mice were sacrificed and organs were harvested. Lung
volumes were weighted and half of the lung tissue was processed for paraffin embedding,
the other half was frozen at -80°C for later DNA analysis. At day 32 there remained 6
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mice injected with MDA-MB-231 shScramble, 6 mice injected with MDA-MB-231
shPDGF C and 3 uninjected mice.
Tissue fixation & staining
The tissue samples were allowed to incubate overnight at 4°C in 4% PFA with gentle
agitation (80 rpm). The tissue samples were dehydrated by incubating for 30 minutes in
70% ethanol, then 30 minutes in 80% ethanol, then 30 minutes in 90% ethanol, then 30
minutes in 95% ethanol, then 20 minutes in 100% ethanol, 20 minutes in 100% ethanol
again, 20 minutes in 100% xylene, 20 minutes in 100% xylene, 1 hour in melted paraffin
(at 55°C), then at last overnight in melted paraffin (55°C). Tissue was then placed in
molds and embedded in melted paraffin for later staining. Fixed & embedded tissue was
hematoxylin & eosin (H&E) stained courtesy of Dr. Larry Tait. Dr. Cher and Dr.
Bonfil’s laboratory allowed use of their microscope to capture images.
Statistical analysis
P-values <0.05 were considered statistically significant.

Real Time PCR error bars

represent standard deviation of triplicates. Error bars were calculated by propagation of
error from the replicate samples as described elsewhere. Data from WST-1 proliferation
were analyzed using IBM® SPSS® Statistics version 22 using repeated measures
ANOVA. Invasion assay bar graph indicates the average number of invading cells
assessed in three high-power fields. Error bars indicate the standard deviation of the
values. T-tests were performed to determine between averages to determine significance.
Soft agar assay bar graph indicates the average number of colonies formed in three wells.
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Error bars indicate the standard deviation of the three wells. T-tests were performed to
determine between averages to determine significance.

For in vivo tumor growth

analysis, Tumor growth was measured at the indicated time points following perimammary fat pad orthotopic injection of female NOD/SCID mice (6 and 7 mice in
shScramble and shPDGF C groups, respectively). Data are mean ± SEM. Lung weight
bar graph indicates average weight (grams). Data are averages with error bars indicating
standard deviation. Box-whisker plots represent the quartiles (25%, median, and 75%).
Dr. Park performed statistical analysis of Kaplan-Meier survival curves showing
probability of disease-free survival with log-rank test, two sided P value.
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CHAPTER 3
RESULTS
3.1 PDGF C gene expression in human breast cancer cell lines.
PDGF signaling has been shown to play an important role in the development and
progression of several types of cancers (as reviewed in [67]). Previous studies have
shown expression of PDGF receptors in human breast cancers and also associated PDGF
receptor staining with poor prognostic features of breast cancer such as metastasis to
lymph nodes and bone metastasis, in addition to association with overexpression of the
oncogene HER2/neu [75-78, 110, 112]. Furthermore, our laboratory’s data and one paper
in the published literature have shown that PDGF C has an alternatively spliced mRNA
variant ([117] and Figure 4, data courtesy of NJH). This newly discovered PDGF C
splice variant mRNA contains an additional 61 base pair retained exon, shifting the
translation start codon thus creating an N-terminally truncated PDGF C variant that our
laboratory designates as truncated-PDGF C (t-PDGF C) while the other group refers to it
as PDGF C-Cb [117].
Since the discovery of the splice variant of PDGF C [117] its function has not yet
been elucidated. In addition, since our laboratory had previously determined by RT-PCR
analysis that PDGF C expression level is correlated with the malignant potential of
human breast cancer cell lines (Figure 4, data courtesy of NJH) we further analyzed the
expression levels of PDGF C and its splice variant in human breast cancer cell lines.
Total PDGF C expression (both FL-PDGF C and t-PDGF C) was analyzed by real time
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Figure 6. PDGF C mRNA expression in breast cancer cell lines. Real-time RT-PCR
analysis of A) Total PDGF C (both FL-PDGF C and t-PDGF C) and B) t-PDGF C in
MCF-10A, MCF-7, T47D, BT-549, MDA-MB-231, SUM102, SUM149, and
SUM190 cell lines. MCF-10A PDGF C RNA level was arbitrarily set as 1 and the
error bars represent standard deviation of triplicates. Error bars were calculated by
propagation of error from the replicate samples.
PCR in a panel of human breast cancer cell lines using primers capable of annealing to
both splice variants (Figure 6A). In addition, by designing one primer within the unique
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retained exon 2’ of t-PDGF C (Figure 5), the level of specifically t-PDGF C was assessed
by real time PCR in the panel of human breast cancer cell lines (Figure 6B). These breast
cancer cells lines were selected for analysis because they cover a range of breast cancer
subtypes, from the non-malignant MCF10A breast cell line to highly aggressive breast
cancer cell lines such as the triple-negative MDA-MD-231 isolated from the metastatic
pleural effusion of breast cancer, and the inflammatory breast cancer cell lines
SUM149PT and SUM190PT [121, 122, 127, 141]. As shown in Figure 6, the nonmalignant MCF10A cell line and the hormone-receptor positive MCF-7 breast cancer cell
line show the lowest levels of total PDGF C expression and t-PDGF C expression. Of
note, there is almost undetectable expression of either total PDGF C or t-PDGF C in the
MCF-7 breast cancer cell line (Figure 6). While the hormone-receptor positive T47D
breast cancer cell line ([121, 122, 128]) has low to intermediate expression of total PDGF
C and t-PDGF C (Figure 6). The more malignant and triple-negative papillary invasive
ductal carcinoma BT-549 breast cancer cell line [121, 122] showed the highest levels of
total PDGF C (Figure 6A) while it had intermediate levels of specifically t-PDGF C
expression (Figure 6B). The very aggressive and invasive triple-negative MDA-MB-231
breast cancer cell line showed the second highest level of total PDGF C expression and
the highest expression of specifically t-PDGF C amongst the panel screened (Figure 6).
Amongst the SUM breast cancer cell lines, the SUM102PT breast cancer cell line had the
lowest expression of total PDGF C or t-PDGF C appearing to express PDGF C similar to
perhaps slightly higher than the T47D breast cancer cell line. The more aggressive
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inflammatory breast cancer cell lines, SUM149PT, and SUM190PT, had higher levels of
total PDGF C and t-PDGF C expression than SUM102PT cells (Figure 6).
This data confirms and quantifies our laboratory’s previous qualitative results via
semi-quantitative PCR (Figure 4, data courtesy of NJH).
3.2 Experimental models.
Very little research has been done to investigate the role of PDGF C in breast
cancer and since it was so recently discovered, often the PDGF C splice variant is not
addressed in studies of PDGF C. In order to better understand the role of PDGF C
isoforms in human breast cancer, this study was undertaken. To that end, breast cancer
cell lines transfected to differentially express FL-PDGF C and t-PDGF C were created.
Semi-quantitative RT-PCR confirms the differential expression of the FL-PDGF C
mRNA and the t-PDGF C mRNA (Figure 7).
The human breast cancer cell line MCF-7 has almost undetectable levels of total
PDGF C or t-PDGF C (Figure 6A & 6B) making this cell line an ideal model in which to
overexpress the PDGF C isoforms (Figure 7). Additionally, human breast cancer cell line
BT-549 has high levels of total PDGF C, but relatively lower levels of specifically tPDGF C RNA (Figure 6A & 6B), making this cell line an ideal model in which to
overexpress the t-PDGF C RNA (Figure 7). While MDA-MB-231 human breast cancer
cell line has relatively high levels of both total PDGF C and t-PDGF C (Figure 6A & 6B),
making it an ideal model in which to knockdown the expression of PDGF C by shRNA
(Figure 7).
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Figure 7. The mRNA expression levels of the PDGF family members in breast cancer
cell models that differentially express PDGF C isoforms. RT-PCR analysis of PDGF
A, B, C, and D, as well as their receptors PDGFR-α, and PDGFR-β in stably
transfected experimental models. 231= MDA-MB-231 transfected cells. ShScram=
scramble shRNA control transfected. ShC= PDGF C shRNA knockdown. EV= empty
vector control transfected. t-C= truncated PDGF C transfected. Neo = control.
transfected. FL-C= Full-length PDGF C transfected. Negative control= dH2O.

Model 1: MCF-7 breast cancer cells which normally express little endogenous PDGF C
were transfected with control vector or full-length-PDGF C (His-tagged) to overexpress
FL-PDGF C or vector control (as described elsewhere, [132]). In addition, later another
set of MCF-7 transfectants were created in order to investigate both PDGF C splice
variants. These MCF-7 breast cancer cells were transfected to overexpress t-PDGF
C/myc or FL-PDGF C/myc or vector control (Figure 7).
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Model 2: MDA-MB-231 breast cancer cells which normally express high levels of both
FL-PDGF C and t-PDGF C mRNA were transfected with control (shScramble) vector or
PDGF C shRNA (shPDGF C) to knockdown PDGF C expression (Figure 7).
Model 3: BT-549 breast cancer cells that express predominantly full-length-PDGF C
were transfected with control vector or t-PDGF C/myc tagged (Figure 7).
PDGF C expression and the entire PDGF family expression was confirmed in the cell line
models by RT-PCR analysis (Figure 7). This demonstrates that the stably transfected
cells express PDGF C isoforms as desired.
3.3 PDGF C custom antibody is specific to PDGF C growth factor domain.

Figure 8. Specificity of PDGF C custom antibody in immunoblot analysis.
Reducing immunoblot (IB) of MCF-7 Neo control vector stable transfected
(N) and MCF-7 FL-PDGF C stable transfected (C) A) conditioned media
probed with our laboratory’s custom PDGF C antibody, and B) whole cell
lysate probed with GAPDH control antibody. Ratios depict Peptide:Antibody
ratios of 2:1, 10:1 and 50:1 molar competition with no peptide as the control.
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Our laboratory’s custom PDGF C antibody is a polyclonal antibody that was
raised in rabbits against a synthetic peptide epitope of the PDGF C growth factor domain
amino acids 230 to 250 (as described in [132]). As demonstrated in Figure 8, detection of
PDGF C protein on western blot can be blocked by incubating the blot with an excess of
PDGF C peptide, while detection of GAPDH is not blocked by an excess of PDGF C
peptide. This demonstrates the specificity of our laboratory’s custom antibody for
detecting PDGF C via western blotting.
3.4 PDGF C is a secreted growth factor.

Figure 9. PDGF C is secreted from breast cancer cells. Reducing immunoblot (IB)
analysis of PDGF C using conditioned media collected from indicated cells A) human
breast cancer cell lines, and B) in transfected experimental models. All conditioned
media is concentrated, except that of MCF-7 FL-PDGF C transfected cells. FL-C or
FL-PDGF C= Full-length PDGF C. 231 = MDA-MB-231. shScram = control shRNA.
shC = PDGF C shRNA. EV = empty vector control. t-C = truncated PDGF C. Neo =
empty vector control. PDGF C GF= PDGF C Growth Factor domain.
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Traditionally PDGF ligands are thought of as secreted growth factors whose
mechanism of action is to act on extracellular PDGF receptors in a paracrine, juxtacrine
or autocrine matter (as reviewed in [79]). Thus it is natural to assess the secretion of
PDGF C in human breast cancer by western blot analysis of the conditioned media of
several breast cancer cell lines (Figure 9A). As shown, there is detectable PDGF C
growth factor domain protein (PDGF C GF) expressed and secreted in some of the
analyzed breast cancer cell lines’ conditioned media, including high levels in the
aggressive triple-negative MDA-MB-231 cells which express both full-length PDGF C
and the splice variant mRNA (Figure 9A). Additionally in our cell line model of MDAMD-231 cells, downregulation of PDGF C expression by stable shRNA knockdown
significantly decreases the amount of PDGF C growth factor domain protein detected on
western blot (Figure 9B). Relatively high levels of PDGF C growth factor domain
protein is also seen in the conditioned media of T47D cells (Figure 9A). Surprisingly
despite high levels of full-length PDGF C mRNA levels, there appears to be relatively
much lower PDGF C growth factor domain protein levels found in BT-549 breast cancer
cells, requiring longer film exposure to detect via western blot analysis (Figure 9A).
Lower than expected protein levels in these cells are presumably due to the high levels of
the PDGF Receptor-α in these cells as seen at the mRNA level via PCR analysis (Figure
7). Presumably autocrine signaling and receptor endocytosis causes there to be rapid
uptake of PDGF C ligand and thus not as much is detected on western blot. Upon stable
transfection and overexpression of the splice variant, t-PDGF C, there is a slight but
consistent increase in the PDGF C growth factor domain protein when equal amounts of
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concentrated conditioned media protein are loaded on western blot (Figure 9B). MCF-7
breast cancer cell line expressed no PDGF C growth factor domain protein as assessed by
western blot (Figure 9A), making it a good model for overexpression of PDGF C. As
seen in Figure 9B, MCF-7 cells stably transfected to overexpress full-length PDGF C
shows very high levels of PDGF C growth factor domain protein in unconcentrated
conditioned media.
In order to investigate possible autocrine signaling the BT-549 cell line model,
downstream signaling molecules and their phosphorylation was assessed in the whole cell
lysates of serum-starved cells. As
shown in Figure 10, there is
higher phospho-Akt and higher
levels of phospho-Erk in BT-549
cells

stably

transfected

to

overexpress t-PDGF C/myc as
compared to control empty vector
transfected BT-549 cells.
Figure 10. Autocrine signaling in BT-549 cell
line model. Whole cell lysates in the indicated
stable transfected cell lines were immunoblotted
with phospho-Akt, total Akt, phospho-Erk, total
Erk and GAPDH. MDA-231= MDA-MB-231.
ShScram = ShRNA scramble control transfected,
ShPDGFC= ShPDGF C knockdown. EV= Empty
vector transfected, Neo= Neo control transfected.

This

data in addition to the lower than
expected PDGF C GF protein
detected in the conditioned media
supports the notion that PDGF C
protein is involved in autocrine
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signaling in cells that express PDGF receptors that PDGF C can active. This data
suggests that PDGF C ligand is secreted into the conditioned media, then quickly taken
up activating the PDGFR-α receptors and causing downstream signaling.
3.5 PDGF C is also a nuclear protein.
A previous study described the nuclear localization of PDGF C in human thyroid
tissue samples, papillary thyroid carcinoma samples, and cell lines [120]. It was found
that nuclear PDGF C was post-translationally modified with the small ubiquitin-like
modifier (SUMO) [120]. This led our laboratory to likewise investigate the cellular
localization of PDGF C in human breast cancer cell lines. Subcellular localization of
PDGF C was analyzed by simple nuclear and cytosolic fractionation in the MCF-7 model
expression cell lines. Full-length PDGF C that has not been proteolytically processed to
the growth factor domain is seen at approximately 50 kilodaltons (kDa) in the cytosolic
fraction, nuclear fraction and secreted into the conditioned media of the stably transfected
MCF-7 cells (Figure 11A). In addition, as expected, full-length PDGF C is secreted into
the conditioned media where it can be proteolytically processed to the PDGF C growth
factor domain (PDGF C GF) and seen at approximately 18 kDa (Figure 11A). In order to
analyze the subcellular localization of endogenous PDGF C in human breast cancer cell
lines, T47D human breast cancer cells were separated into several subcellular fractions
and subjected to western blot analysis. Full-length PDGF C not proteolytically processed
(~50 kDa) can be seen in the conditioned media of the positive control, MCF-7 FL-PDGF
C/myc transfected lane (Figure 11B). Also, there is a slightly higher molecular weight
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Figure 11. Nuclear localization of PDGF C in breast cancer cells. A) Reducing
immunoblot of MCF-7 stable transfectant cells probed with PDGF C, GAPDH and
histones antibodies. B) Reducing immunoblot of T47D parental subcellular fractions
probed with the indicated antibodies. EV= MCF-7 Empty Vector transfected. t-C=
MCF-7 t-PDGF C/myc transfected. FL-C= MCF-7 FL-PDGF C/myc transfected. Cy=
Cytoplasmic, Me= Membrane, SN= Soluble Nuclear, CB= Chromatin Bound Nuclear,
CK= Cytoskeletal, CM= T47D concentrated conditioned media, and + indicates MCF7 FL-PDGF C/myc conditioned media, as a positive control.
band (~60 kDa) in the conditioned media of T47D cells that may represent full-length
PDGF C unprocessed in that cell line (Figure 11B). Interestingly the proteolytically
processed PDGF C growth factor domain protein is found predominantly in the
chromatin bound nuclear fraction of T47D breast cancer cells (Figure 11B) with a smaller
amount found in the cytoskeletal and concentrated conditioned media (Figure 11B). This
is in agreement with published literature showing nuclear PDGF C can be detected in the
chromatin bound fraction of cultured NIH/3T3 cells [120]. Additionally, in T47D cells
there are multiple faint bands detected between the 25 kDa and 37 kDa molecular weight
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markers in the chromatin bound nuclear fraction (Figure 11B). This may represent
endogenous t-PDGF C, as the PDGF C splice variant protein product has been shown to
be expressed in a similar manner, as multiple bands of a similar size, in both transfected
COS-7 cells and endogenous in a human malignant glioma cell line in the literature
[117]. Nuclear localization of PDGF C in breast cancer cell lines is a novel finding and is
potentially clinically relevant.
3.6 AEBSF, an irreversible serine protease inhibitor, prevents PDGF C processing.
Since it was difficult to detect t-PDGF C in our overexpression cell line models
(Figure 11A), we undertook experiments aimed at inhibiting the processing and
degradation of protein in case t-PDGF C was being rapidly subjected to proteases thus
making it difficult to detect. Our laboratory’s previous study identified aprotinin, a serine
protease, as an inhibitor of PDGF C processing in human breast cancer cell lines [132].
The inhibitors diisopropyl fluorophosphate (DFP) and phenylmethanesulfonylfluoride
(PMSF) irreversibly inactivate serine proteases by reacting with serine 195 generating a
stable transition state adduct (as reviewed in [142]). However due to toxicity DFP is not
considered safe to handle and although less toxic, PMSF is not considered stable.
Sulfonyl Fluorides were discovered to be inhibitors of serine proteases and began to be
characterized by Fahrney and Gold ([143], and as reviewed in [144]). The sulfonyl
fluoride known as 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) is
known by the trade name Pefabloc® SC (Pentapharm, [145]). It is an irreversible serine
protease inhibitor that is water soluble and less toxic than the serine protease inhibitor
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phenylmethanesulfonyl fluoride (PMSF), and considered stable in aqueous solutions
making it particularly useful for cell culture use [145-147]. AEBSF is relatively small
molecular weight of 239 Daltons [145], and is cell permeable [148-150]. It has been
shown to inhibit a range of
serine proteases including
ones relevant to activation of
PDGF’s

by

proteolytic

processing such as plasmin,
tPA, uPA and recombinant
human matriptase [151]. In
an

in

vitro

human

experiment,
recombinant

matriptase was inhibited by
AEBSF [151].
Figure 12. Serine proteases proteolytically process
PDGF C. Reducing immunoblot (IB) probed with
PDGF C antibody (top), GAPDH (bottom). Whole cell
lysate (left) and conditioned media (right) from T47D
parental breast cancer cells. dH2O Vehicle = deionized,
distilled water vehicle control treatment, DMSO =
dimethyl sulfoxide vehicle control treatment, AEBSF =
4-(2-Aminoethyl)benzenesulfonyl fluoride
hydrochloride (AEBSF) dissolved in dH2O treatment,
PI Cocktail = Protease inhibitor cocktail dissolved in
DMSO. All treatments 48-hrs in serum free media.

In order to

investigate the inhibition of
endogenous

PDGF

C,

T47D cells were serum
starved for 48 hours with a
commercially

available

protease inhibitor cocktail,
AEBSF, or vehicle control

treated (Figure 12). Only the irreversible serine protease inhibitor AEBSF acted to
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sufficiently inhibit the full-length PDGF C proteolytic processing of PDGF C to the
growth factor domain (GF domain, Figure 12). In addition, AEBSF treatment appears to
allow for the accumulation of full-length PDGF C in these cells as evidenced by a darker
band at ~60 kDa in the AEBSF treated condition (Figure 12).

The commercially

available protease inhibitor cocktail did not inhibit the processing of PDGF C as well as
AEBSF inhibition did (Figure 12).

This may be explained by the fact that the

Figure 13. AEBSF is a potent inhibitor of PDGF C processing. Immunoblot (IB)
analysis of MCF-7 cells stable transfected with FL-PDGF C/myc A) conditioned
media, and B) whole cell lysates. Each blot has reducing samples (left) and nonreducing samples (right). dH2O vehicle indicates, vehicle control of serum-free
media with dH2O added in lieu of a protease inhibitor. FL-C= Full-length PDGF C,
Hemi dimer = Full length PDGFC dimer with one CUB domain removed. GF
domain= growth factor domain.

53

commercially available protease inhibitor cocktail contains the reversible serine protease
inhibitor, aprotinin, while AEBSF is an irreversible serine protease inhibitor. Aprotinin
alone appears to be unable to completely inhibit PDGF C processing to the active growth
factor domain (~18 kDa, Figures 13 and Figure 14). However, Aprotinin appears to
stabilize the hemi-dimer (as seen on non-reducing blots) and the growth factor domain
(as seen on both reducing and non-reducing blots) (Figure 13 and Figure 14). This is
seen to accumulate, possibly due to inhibition of the further proteolytic processing, or
degradation, of the PDGF C growth factor domain. Interestingly, the irreversible serine
protease inhibitor AEBSF is found to be very effective at inhibiting the processing of
full-length PDGF C to the hemi-dimer and inhibiting to processing to the subsequent
growth factor domain dimer (Figure 13 and Figure 14). Thus the two step processing of
full-length PDGF C appears to be predominantly due to serine proteases in the breast
cancer cell lines MCF-7 cells and T47D cells. Unfortunately the t-PDGF C/myc tagged
protein was not detected via western blot analysis even with irreversible serine protease
inhibition of the MCF-7 stably transfected overexpressing cell lines (Figure 14). Thus we
conclude that the difficulty in detecting t-PDGF C is likely not due to it being subjected
to proteolytic degradation.

54

Figure 14. Serine protease inhibition effectively prevents proteolytic processing of
PDGF C. Immunoblot (IB) analysis of conditioned media from MCF-7 cells stable
transfected with Empty Vector (EV), Truncated PDGF C/myc-tagged (t-C), or Fulllength PDGF C/myc-tagged (FL-C). Samples were treated with vehicle control,
Aprotinin (a reversible serine protease inhibitor), or AEBSF (an irreversible serine
protease inhibitor). A) Reducing blot, B) non-reducing blot, probed with myc-tag
antibody. FL-C = Full-length PDGF C. GF= growth factor domain. Hemi-dimer =
Full-length PDGF C and growth factor domain hetero-dimer.

3.7 Truncated PDGF C can be secreted as a dimer with full-length PDGF C and
proteolytically processed by the serine protease matriptase into an active growth
factor domain dimer.
The only study published in the literature describing the PDGF C splice variant,
describes the PDGF C splice variant protein product, t-PDGF C, as an intracellular
protein [117]. Due to technical difficulties in detecting t-PDGF C in our breast cancer
cell line models, we were unable to detect t-PDGF C when overexpressed in MCF-7
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breast cancer cells despite using an expression vector with a myc-tag and inhibiting
proteases. Realizing that in human breast cancer cell lines, t-PDGF C mRNA does not
appear to be expressed alone in cells, but instead it is expressed along with the full-length
PDGF C mRNA transcript (Figure 4, data courtesy of NJH). These observations lead us
to believe that protein stability of t-PDGF C may be a problem when t-PDGF C is
expressed without full-length PDGF C. We further hypothesized that t-PDGF C may
need to be expressed with full-length PDGF C in our cell line models in order to be able
to detect the protein. Since MCF-7 breast cancer cells do not express PDGF C at the
RNA level, we focused our efforts to detect t-PDGF C protein on the BT-549 cell model
which naturally expresses predominantly full-length PDGF C.

In BT-549 cells

transfected to overexpress t-PDGF C/myc tagged, after much troubleshooting, it was
discovered that the myc-tag antibody used in an attempt to try to detected t-PDGF C/myc
in the stably transfected BT-549 cells did not work well under reducing conditions
(Figure 15A).

However, the myc-tagged antibody worked much better under non-

reducing SDS-PAGE western blotting conditions (Figure 15A). To our surprise when
conditioned media samples from the BT-549 t-PDGF C/myc transfected cells were run
under non-reducing conditions, t-PDGF C/myc can be detected secreted from the cells
(Figure 15). Furthermore, this secreted t-PDGF C/myc is of a unique molecular weight
as compared to the intracellular t-PDGF C/myc protein detected under non-reducing
conditions (Figure 15). The difference in molecular weight of the intracellular myctagged t-PDGF C as compared to the molecular weight of the extracellular myc-tagged tPDGF C in this BT-549 model system suggests that t-PDGF C may be secreted as a
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hetero-dimer with a larger protein, presumably endogenous full-length PDGF C, while

Figure 15. Truncated PDGF C is secreted into the conditioned media as a heterodimer
with FL-PDGF C. Immunoblot (IB) analysis of A) Whole Cell Lysate (WCL),
Concentrated Conditioned Media (Conc CM), or Conditioned Media (CM) from BT549 cells stable transfected with empty vector (EV or 549 EV) or t-PDGF C/myctagged (t-C or 549 r-C/myc) and MCF-7 transfected with Full-length PDGF C (MCF7
FL-C/myc) conditioned media. Immunoblot analysis of B) conditioned media samples
after incubation with recombinant human matriptase for the indicated times.
intracellular t-PDGF C is presumed to be a t-PDGF C homo-dimer. Importantly, the
myc-tagged t-PDGF C secreted into the conditioned media can be proteolytically
processed by the serine protease matriptase to produce the PDGF C growth factor domain
(Figure 15B). The PDGF C splice variant being capable of being secreted is a novel
finding. Zhao, et al concluded that the t-PDGF C protein (designated PDGF-Cb in their
publication) is an intracellular protein [117]. Here we show that t-PDGF C/myc tagged
protein can be secreted when expressed in a human breast cancer that also expresses
endogenous full-length PDGF C. This suggests that t-PDGF C is capable of being an
intraceullular, and extracellular protein.

Furthermore, here we show that the serine

protease matriptase is able to proteolytically process this secreted t-PDGF C/myc. Thus
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presumably, secreted t-PDGF C could act as a reservoir of more active PDGF C growth
factor domain and it may be capable of extracellular activation of PDGF receptors.
In order to further analyze the PDGF C isoforms detected, samples were run on a
low percent acrylamide gel by SDS-PAGE for an extended period of time in order to
better resolve the molecular weights of the various protein entities under non-reducing
conditions (Figure 16). The full-length PDGF C homodimer can be detected by both the
myc-tag antibody and our laboratory’s custom PDGF C antibody (Figure 16A & B).
Furthermore, the partially proteolytically processed hemi dimer (one CUB domain
removed) can be seen in the full-length PDGF C transfected conditioned media. This
protein entity is distinct from the newly discovered t-PDGF C heterodimer. Finally, the
whole cell lysates show predominantly protein of the t-PDGF C homodimer molecular
weight. Of note, the PDGF C antibody does not appear to detect the t-PDGF C protein
species (Figure 16B). This may explain the previous difficulty in detecting t-PDGF C
protein in transfected cells. The three dimensional conformation of t-PDGF C protein
may be altered such that the PDGF C antibody is not able to access the epitope, resulting
in poor detection via western blot. Thus, creation of a t-PDGF C custom antibody may
be helpful in order to be able to better detect endogenous t-PDGF C in the future.
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Figure 16. Heterodimerization of truncated PDGF C. Non-reducing immunoblot (IB)
analysis of BT-549 empty vector transfected (EV), BT-549 t-PDGF C/myc transfected
(t-C), and MCF-7 Full-length PDGF C/myc transfected (FL-C) CM = conditioned
media, and WCL= whole cell lysates. A) Probed with myc-tag antibody, and B)
probed with PDGF C antibody. BT-549 conditioned media is concentrated.

3.8 Mutating a putative nuclear localization sequences does not abolish nuclear
localization of PDGF C.
A previous report demonstrating nuclear PDGF C suggested a putative nuclear
localization sequence in the amino acids of PDGF C [120]. In order to investigate if this
putative nuclear localization sequence is responsible for PDGF C nuclear localization, we
mutated four basic amino acids of the putative nuclear localization sequence to alanine
(R312A/K314A/R318A/K322A) and subsequently transiently transfected COS-1 cells
(Figure 17). RT-PCR analysis shows that the cells express PDGF C after transient
transfection (Figure 17A). Mutating the nuclear localization sequence does not affect the
secretion of PDGF C into the conditioned media, nor does it appear to affect the
proteolytic processing of PDGF C into the growth factor domain (Figure 17B).
Furthermore, the mutated putative nuclear localization sequence does not appear to
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inhibit the nuclear localization of PDGF C. In the nuclear fraction of the cells, not only is
full-length PDGF C seen at ~50 kDa, but also the proteolytically processed PDGF C
growth factor domain is seen at ~18 kDa (Figure 17C). Thus we conclude that the
putative nuclear localization sequence published in the literature does not appear to be
crucial for PDGF C nuclear localization.

Figure 17. Mutation of putative nuclear localization sequences does not diminish
nuclear localization of PDGF C. A) PCR, B) immunoblot analysis of conditioned
media, and C) immunoblot analysis of cytosolic and nuclear fractions. COS-1 Parental
(P), COS-1 transfected with Empty Vector (EV), Wild Type PDGF C/His expression
vector (WT) or mutant PDGF C expression vectors (three independent expression
plasmid preparations; colony 1, colony 2, or colony 3). – indicates dH2O negative
PCR control. + designates conditioned media from MCF-7 stably transfected with FLPDGF C/His.
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3.9 Amino acids in the hinge region are important in PDGF C subcellular
localization.
In our laboratory’s previous study, the cleavage site of PDGF C by serine
proteases was identified as arginine and lysine amino acids in the hinge region [132]. A
cleavage-deficient mutant was generated and expressed in a vaccinia virus expression
system [132]. By mutation of those key amino acids in the hinge region of PDGF C
(K225A/R231A/R234A, “cleavage-deficient PDGF C”) our laboratory showed that those
residues are important in the proteolytic processing and activation of PDGF C [132]. In
order to investigate the importance of these crucial amino acids on the subcellular
localization of PDGF C, MCF-7 cells which do not naturally express PDGF C were
infected-transfected with either empty vector, wild type PDGF C, or the cleavagedeficient mutant PDGF C vaccinia vectors and expression was confirmed (Figure 18A).
Wild type PDGF C is secreted and proteolytically processed in the conditioned media
while the cleavage-deficient mutant PDGF C protein is not secreted (Figure 18B). Wild
type PDGF C is predominantly found as full-length PDGF C (~50 kDa) in the cytosol
while it is predominantly the proteolytically processed growth factor domain in the
nuclear fraction (Figure 18C). The cleavage-deficient PDGF C appears to accumulate as
full-length PDGF C (~50 kDa) in the cytosol, but the proteolytically processed growth
factor domain is absent from the nuclear fraction (Figure 18). This suggest that amino
acids in the hinge region are crucial for not only proper proteolytic processing by serine
proteases as our previous study indicated [132], but they may also play an important role
in the subcellular localization of PDGF C.
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Figure 18. The serine protease cleavage site in the hinge region is critical for the
subcellular localization of PDGF C. A) RT-PCR, immunoblot analysis in the reducing
condition using B) conditioned media and C) cytosolic (cyto) or nuclear fractionation
of MCF-7 cells engineered to express Empty Vector (EV), PDGF C wild type (WT),
or PDGF C cleavage-deficient triple mutant (TM) using vaccinia virus expression
system. – indicates dH2O PCR negative control, + indicates conditioned media from
MCF-7 stably transfected with FL-PDGF C/His-tag as a positive control.

3.10 Deletion of the putative PDGF C signal sequence abolishes secretion and
proteolytic processing.
Since previous experiments indicate that both full-length PDGF C and
proteolytically processed PDGF C growth factor domain can be found in the nuclear
fraction of cells, we further investigated where the proteolytic processing takes place. To
this end, a mutant PDGF C vector was constructed that lacks the putative signal sequence
of PDGF C. Transient transfection of the deleted signal sequence PDGF C mutant vector
in COS-1 cells shows RNA expression of the vectors (Figure 19A) and shows that
secretion is abolished when the signal sequence is deleted (Figure 19B). Furthermore, it
appears that there is no PDGF C growth factor domain detected in the whole cell lysate of
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the deleted signal sequence PDGF C mutant (Figure 19B). This experiment was carried
out with or without the presence of the irreversible serine protease inhibitor AEBSF in
the event that proteolytic degradation might affect detection of mutant PDGF C (Figure
19 +/- AEBSF lanes). It does not appear that the mutant protein is being degraded.
Furthermore, it does not appear that the mutant protein is capable of being proteolytically
processed as no growth factor domain is detected (Figure 19B). Thus we conclude that
the putative signal sequence is in fact important in the secretion of full-length PDGF C.
Furthermore, secretion is likely necessary for proteolytic processing of PDGF C.

Figure 19. Deletion of the putative PDGF C signal sequence prevents PDGF C
secretion. A) RT-PCR analysis and B) reducing immunoblot analysis (IB) in COS-1
cells that are transient transfected with empty vector (EV), PDGF C expression vector
lacking the signal sequence (∆SS) or wild type PDGF C (FL-C). dH2O= PCR negative
control. + indicates addition of AEBSF protease inhibitor, – indicates no AEBSF.

63

3.11 The functional significance of PDGF C isoform expression in breast cancer.
We hypothesized that higher PDGF C expression induces transformation and a
more invasive phenotype.

We further hypothesized that t-PDGF C enhances the

oncogenic potential of FL-PDGF C in breast cancer cells. Overexpression of the splice
variant, t-PDGF C, in BT-549 cells which naturally express predominantly full-length
PDGF C, causes phenotypic transformation. In an in vitro invasion assay, the t-PDGF
C/myc overexpressing BT-549 cells were more invasive than parental BT-549 cells or
empty vector transfected BT-549 cells (Figure 20).

Furthermore, in vitro soft

Figure 20. Truncated PDGF C overexpression increases the invasiveness of breast
cancer cells. In vitro Matrigel™ invasion assay of parental and BT-549 stable
transfected with empty vector (EV) or t-PDGF C/myc. Left, invading cells stained on
filters. Right, bar graph indicates an average of the number of invading cells in
triplicates. The bars indicate the standard deviation of the values. NS= not significant.
*= significant.
agar colony analysis shows significantly more colonies in the t-PDGF C overexpressing
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BT-549 cells when analyzing for colonies 75-300 µm in size (Figure 21).

In order

Figure 21. Truncated PDGF C overexpression increases soft agar colony formation of
breast cancer cells. A) PCR of BT-549 Empty Vector stable transfected (EV) and
BT549 t-PDGF C/myc stable transfected (t-C) cells, B) Soft agar colony formation,
representative microscopic images of colonies were obtained at 40X magnification, C)
Quantitation of the average number of colonies form three wells, with standard
deviation depicted by error bars.
to analyze the overall effect of knockdown of PDGF C expression, soft agar colony
formation was also analyzed in the MDA-MB-231 cell model (Figure 22). Knockdown
of PDGF C expression significantly decreases soft agar colony formation (Figure 22B).
In addition, knockdown of PDGF C expression significantly reduces cellular proliferation
under both serum-containing and low-serum conditions, as compared to control
transfected cells (Figure 22C & D).
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Figure 22. PDGF C knockdown decreases proliferation & soft agar colony formation.
MDA-MB-231 scramble transfected (shSc, shScramble) and MDA-MB-231 PDGF C
knockdown (shC, shPDGF C) A) PCR analysis of PDGF C expression, B) soft agar
colony formation, average of colonies formed. Error bars indicate standard deviation
of triplicate replicates. C) proliferation in under normal serum-containing conditions,
and D) proliferation in low serum (1%) conditions.

3.12 PDGF C expression in vivo.
We hypothesized that PDGF C expression induces oncogenic cell signaling in
autocrine and paracrine manners to increase proliferation and invasive ability of tumor
cells as well as to mediate stromal responses critical for tumor cell invasion and
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metastasis. In order to investigate the role of t-PDGF C in human breast cancer, the
stably transfected BT-549 cells were injected into the peri-mammary fat pad of mice and
tumor growth was assessed (Figure 23A).

Unfortunately the BT-549 human breast

cancer cells did not grow well in this animal model and the small palpable tumors began
to regress after approximately 14 days (Figure 23A). However, the slight growth that
was detected in the period before tumor regression of the t-PDGF C/myc overexpressing
cells as compared to control empty vector transfected suggests that the overexpression of
t-PDGF C may be pro-oncogenic. Because the BT-549 cells were not able to form
lasting tumors, injection of more cells, such as 5x106 cells may be necessary for lasting
xenograft tumor formation with BT-549 cells as one study in the literature has since
successfully done [152], or a more tumorigenic breast cancer cell line should be selected
to further investigate the in vivo effects of t-PDGF C overexpression on breast cancer
tumor growth. Using the GOBO data (Figure 2) and our laboratory’s previous semiquantitative PCR analysis of PDGF C expression in cell lines (Figure 4, data courtesy of
NJH) a cell line shown in the literature to be more tumorigenic in orthotopic animal
models could be selected for future animal studies.
MDA-MB-231 cells successfully form tumors in mice [153].

Furthermore,

increased tumor take is observed when MDA-MB-231 cells are injected in the mammary
fat pad as opposed to subcutaneous tumor cell injection [153]. In an orthotopic mouse
model, MDA-MB-231 human breast cancer cells were injected peri-mammary fat pad
and tumor growth was assessed. Before injection, PDGF C expression was assessed by
PCR (Figure 23B). MDA-MB-231 PDGF C knockdown cells (MDA-MB-231 shPDGF
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C) grew smaller tumor volumes that the control transfected cells (MDA-MB-231
shScramble, Figure 23B).

Figure 23. PDGF C knockdown decreases tumor growth in vivo. 1x106 cells in 50 µL
of Matrigel™/media mix of BT-549 Empty Vector (EV), BT-549 t-PDGF C/myctagged (t-C), or MDA-MB-231 shScramble (ShSm), MDA-MD-231 shPDGF C (ShC)
stable transfected cells were injected into the perimamary fat pad of NOD/SCID mice.
A) RT-PCR analysis of PDGF C expression (top), and tumor growth of BT-549
Empty Vector or BT-549 t-PDGF C transfected (bottom) measured at the indicated
time points. B) RT-PCR analysis of PDGF C expression (top), and tumor growth
measured at the indicated time points (bottom) of MDA-MB-231 shScramble control
transfected or MDA-MB-231 shPDGF C knockdown transfected cells. Data are mean
± SEM.
Metastases are a serious threat to cancer patients and particularly breast cancer patients
are at risk of spread to vital organs [26, 27]. In order to investigate alteration of PDGF C
expression on breast cancer metastases, MDA-MB-231 stably transfected breast cancer
cells were used in a metastasis animal model experiment. After tail vein injection of
MDA-MB-231 control transfected or PDGF C knockdown cells, lungs were harvested
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and analyzed (Figure 24). There was a trend for smaller lung weight when PDGF C
expression is knocked down (MDA-MB-231 shPDGF C, Figure 24B) however the
difference in lung weights were not significantly different between control transfected
and PDGF C knockdown (Figure 24B). Harvesting of the lungs at an earlier time point
may be necessary in the future in order to have the ability to detect a significant
difference in the metastatic ability of MDA-MB-231 PDGF C knockdown versus the
control transfected cells.

Figure 24. PDGF C knockdown may decrease lung metastases. MDA-MB-231
shScramble control (shScram) transfected cells or MDA-MB-231 shPDGF C
knockdown (shC) transfected cells, 1x106 cells in 100 µL of PBS injected into the
trail vein of SCID mice. A) Lungs collected B) Lung weight (grams) C) H&E stain of
embedded sections 100X magnification. Data are averages with error bars indicating
standard deviation. NS= not significant. *= significant.
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CHAPTER 4
Discussion & Future Directions
Summary of Findings
This study further supports PDGF C as the significant PDGF ligand in human
breast cancer.

In human breast cancer cell lines increased PDGF C expression is

correlated with clinical and pathologic features that confer a poor prognosis, as
demonstrated by higher PDGF C expression in triple-negative breast cancer cell lines
(Figure 4, data courtesy of NJH, Figure 3, & Figure 6).

Additionally, PDGF C

expression was high in HER2/neu overexpressing cell lines (Figure 4, data courtesy of
NJH, Figure 3, & Figure 6) and may be increased in the inflammatory breast cancer cell
lines (Figure 4, data courtesy or NJH). This study’s findings demonstrate that higher
expression of PDGF C isoforms are associated with more aggressive characteristics in
breast cancer cells in vitro and in vivo, including higher cellular proliferation, invasion,
tumor growth, and possibly metastatic growth. Knockdown of PDGF C expression lead
to a reduction in tumor growth, and cellular proliferation.
Furthermore, this study demonstrates the complexity of PDGF C in human breast
cancer due to not only its recently discovered splice variant, and proteolytic processing of
PDGF C, but also due to the varying subcellular localization of PDGF C isoforms in
human breast cancer cells. According to the published literature, the novel PDGF C
isoform, truncated PDGF C, generated from the PDGF C splice variant is described as an
intracellular protein [117]. Initially this finding made sense as the t-PDGF C protein was
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believed to lack a signal peptide due to the premature stop codon in the retained exon,
exon 2’ of t-PDGF C (Figure 5). However, of note, the current study demonstrates for
the first time to our knowledge the ability of the PDGF C splice variant isoform to be
secreted into the conditioned media of transfected cells (Figure 15A). Furthermore, this
study demonstrates that matriptase, a serine protease shown previously by our laboratory
to process full-length PDGF C [132], also has the ability to proteolytically process the
newly discovered secreted truncated PDGF C isoform to the growth factor domain in
vitro (Figure 15B). This significant finding suggest that the protein product of the PDGF
C splice variant, truncated PDGF C, could serve as a repository for more active PDGF C
growth factor domain in the extracellular milieu, thus making it a possible source of
extracellular pro-oncogenic signaling in cancer.
In addition, to our knowledge, never before has PDGF C been localized to the
nuclear fraction in human breast cancer cell lines. This study is the first to show the
proteolytically-processed growth factor domain of PDGF C in the nucleus of human
breast cancer cell lines that naturally express PDGF C (Figure 11). The only study known
in the published literature demonstrates PDGF C as larger molecular weight PDGF C
entities in the nuclear fraction human thyroid cells [120]. In the current study we show
full-length PDGF C in the nuclear fraction of human breast cancer cells transfected to
ectopically express PDGF C, however in T47D human breast cancer cells that express
endogenous PDGF C, nuclear PDGF C appears to be in the proteolyically processed
growth factor domain (Figure 11). In addition, here we show that amino acids in the
hinge region of PDGF C appear to be crucial to subcellular localization, while a putative
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nuclear localization sequence described in the literature did not appear as important
(Figure 18 and Figure 17).
Heterodimerization of FL-PDGF C and t-PDGF C
The mechanism for secretion of truncated PDGF C is unknown and warrants
further investigation. The premature stop codon in the second exon unique to the PDGF
C splice variant encoding truncated PDGF C occurs after the signal sequence of PDGF C,
previously presumed to lead to an alternative translational initiation. Lacking the signal
peptide important for secretion of proteins, one can only speculate how truncated PDGF
C may be secreted into the conditioned media of human breast cancer cell lines. One
hypothesis possibly explaining the secretion of truncated PDGF C involves a pause in the
translation of the truncated PDGF C mRNA while it is being translated. It has been
shown that ribosomes translate mRNA at different speeds for various reasons including to
allow for protein folding, and frameshifts (as reviewed in [154]). When the ribosome
reaches the stop codon in the retained exon of PDGF C, it could be possible that the
ribosome does not disengage translation upon reaching the stop codon, but pauses before
it resumes translation at the alternative start codon with the nascent signal peptide still
attached. This could allow the t-PDGF C protein to have a signal peptide and be secreted
from the cell through the traditional secretory pathway.
Further studies are needed to understand how t-PDGF C is secreted from the cell
as seen in transfected cells (Figure 15). In addition, further studies are needed to analyze
endogenous t-PDGF C localization. With the development of better detection techniques,
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endogenous t-PDGF C expression and localization should be assessed to answer these
questions.
Technical Challenges
Initially the lack of an antibody specific to the truncated PDGF C isoform proved
very challenging when attempting to detect t-PDGF C expression in human breast cancer
cell lines. In the future specific antibodies developed for truncated PDGF C peptide
versus full-length PDGF C, would help immensely in detection of the t-PDGF C and
facilitate teasing apart the fucntions of the PDGF C isoforms from each other.
Another significant challenge to fully understanding the role of each PDGF C
isoform in the field of PDGF research is a lack of expression data for each PDGF C
mRNA variant. Microarray results prevalent in current research only show overall PDGF
C mRNA expression and do not distinguish between the truncated PDGF C splice variant
expression from the full-length PDGF C expression level.
Significance & Future Directions
PDGF C has been shown to play an important role in normal development while
its aberrant expression has been implicated in many pathological conditions including
several types of cancer. Evidence of the importance of PDGF signaling in breast cancer
development and metastases has been accumulating [75-78, 110-113]. Here we provide
further evidence for the importance of PDGF C signaling in human breast cancer. Our
laboratory’s previous findings found no correlation of PDGF A, PDGF B, or PDGF D
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expression with the clinical or pathologic characteristics of breast cancer cell lines
(Figure 4, data courtesy of NJH and manuscript in preparation). Furthermore, recent
findings with collaborators found little to no expression of PDGF D by
immunohistochemical staining of invasive breast cancer tissue samples (unpublished
observation).

However, PDGF C immunohistochemical staining was found to be

significantly correlated with poor prognostic clinical and pathological characteristics such
as lymph node metastasis, HER2/neu overexpressing tumors, and high Ki-67 staining, a
marker for proliferation (manuscript in preparation).
GOBO data further demonstrates that PDGF C expression is significantly
different amongst breast cancer cell lines grouped by clinical and pathological features,
with the highest PDGF C expression in triple-negative breast cancer cell lines (Figure 3).
This is of significance as the treatment of triple-negative breast cancer in the clinic has
been challenging. Expression of the hormone receptors, estrogen and progesterone, or
expression of HER2/neu oncogene allows for more treatment options such as the use of
hormone targeting therapies or treatment that targeting the HER2/neu receptor. However
triple-negative breast cancers do not express any of those receptors, and thus lack
targeted treatment options.

A better understanding of triple-negative breast cancer

biology is needed in order to develop drugs that can target that subset of breast cancers.
Furthermore, a significant problem in the treatment of all cancers is the
development of treatment resistant cancer. Additionally, despite the appearance of being
cured of a cancer, there is always the possibility of cancer recurrence months or years
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later in any cancer patient. Cancer stem cells are believed to be a cause of tumor
recurrence, treatment resistance, and metastases (as reviewed in [155]). These cancer
stem cells are believed to be a subpopulation of cells within cancerous tumors that are
resistant to treatments and thus remain after “curative” treatment, then capable of driving
the recurrence of the cancer [155].

In breast cancer, cancer stem cells have been

determined to express CD44+/CD24–/low cell surface proteins [114]. Thus in order to be
able to permanently cure cancer patients it is important to understand the differences in
these therapy resistant subpopulations of tumors to specifically eradicate those cancer
stem cells along with the bulk of remaining tumor cells [155]. Recent studies provide
mounting evidence for the importance of PDGF signaling, including specifically PDGF
C, in therapy resistant cancer cells and in cancer stem cells [156]. In an effort to identify
ways to target breast cancer stem cells, one study used proteome analysis to demonstrate
an increase in PDGF signaling in a population of HMLE cells that had undergone EMT
(epithelial-mesenchymal transition) by forced expression of twist, while the non-cancer
stem cell epithelial-like population of cells demonstrated higher EGFR signaling [156].
Furthermore, utilizing quantitative PCR this study also showed that Basal B subtype
breast cancer cell lines expressed higher RNA levels of the PDGF receptors, PDGFRA
(encoding PDGFRα) and PDGFRB (encoding PDGFRβ), along with increased RNA
expression of the ligand PDGF C, thus the authors suggest that PDGF C autocrine
signaling may play a role in EMT [156]. Increased expression of PDGF C in Basal B
breast cancer cell lines demonstrated in that study is further corroborated by the GOBO
analysis of PDGF C expression (Figure 2A).

75

Recently several studies have shown that therapy resistant tumors express high
levels of PDGF C suggesting as a possible mechanism of escape. One such study
examining tumors resistant to anti-VEGF treatment, found that there was an increase in
PDGF C expression to compensate for a loss of VEGF signaling [157]. In another study
of therapy resistant tumors, PDGF C was found to be differentially expressed in
squamous cell carcinoma cell lines resistant to cisplatin chemotherapy as compared to
derivative cell lines that were sensitive to cisplatin [158]. Furthermore, this study also
showed that PDGF C expression was one of five genes that predicted patient outcomes
after chemotherapy treatment, suggesting its importance in drug resistance mechanisms
[158].
In another study of chemotherapy resistant breast cancer cells, doxorubicinselected MCF-7 breast cancer cells, showed a 39.3-fold increase in PDGF C expression
by microarray analysis (Figure 25A). The doxorubicin-resistant MCF-7 cells were found
to be both more motile and more invasive in an invasion assay as compared to the MCF-7
parental cells [4]. This study further showed that MCF-7 doxorubicin-resistant cells had
significantly more breast cancer stem cells (CD44+/CD24– cells) than the parental MCF-7
cells (more than 30% in doxorubicin-resistant cells versus less than 0.05% in the
parental) [4]. Furthermore, this study also showed that that the doxorubicin-resistant
MCF-7 cells had a 126.0-fold decrease in estrogen receptor 1 (ESR1) expression as
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Figure 25. Drug resistant breast cancer cells show increased PDGF C expression and
decreased estrogen receptor expression. Box-whisker plots of GEO Data for A)
PDGF C expression, and B) Estrogen Receptor Expression. Graph generated using
GEO data [3] from GEO Data Set 4084 [4].
compared to MCF-7 parental cells (Figure 25B), and were capable of forming tumors in
mice without estrogen supplementation [4]. Normally MCF-7 breast cancer cells require
estrogen supplementation for in vivo tumor growth [159]. Thus confirming that the drug
resistant cells had also become estrogen independent while also having increased PDGF
C expression [4]. Thus doxorubicin-resistance was associated with an increase in breast
cancer stem cell population, an increase in PDGF C expression and it was also associated
with hormone (estrogen) independent disease [4].
In another study, siRNA-mediated silencing of estrogen receptor expression in the
breast cancer cell line MCF-7 caused an approximately 50-200 fold increase in the PDGF
C expression via microarray analysis, again supporting a possible link between hormone
receptor expression and PDGF C expression [160, 161]. These studies bolster the case
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for PDGF C playing an important role in therapy resistant breast cancer in addition to
suggesting a possible interaction between PDGF C expression and estrogen receptor
expression in breast cancer. The GOBO analysis findings above further corroborate this
inverse relationship between PDGF C expression and estrogen receptor expression, as the
hormone receptor positive breast cancer cell lines had the lowest expression levels of
PDGF C (Figure 3) as do our laboratory’s findings that hormone receptor positive breast
cancer cell lines such as MCF-7 have little to no PDGF C expression while triplenegative (i.e. hormone receptor negative, by definition) breast cancer cells lines such as
MDA-MB-231 tend to have much higher PDGF C expression (Figure 6).
Finally, nuclear localization promotes PDGF C to the elite status of growth
factors with nuclear functions. Other growth factors have recently been discovered to
have nuclear localization and nuclear functions. Heparin-binding growth factor-1, also
known as fibroblast growth factor-1 (FGF-1) is a mitogen for mesenchymal cells that was
found to localized to the nucleus [162]. Lack of its nuclear localization sequences
abolished mitogenic activity of the growth factor suggesting that nuclear translocation is
necessary for its activity [162, 163].
PDGF C being localized to the nucleus greatly complicates the possible roles for
such multi-tasking growth factors in the development and progression of cancer, as their
effects are not necessarily exclusively extracellular actions on their respective receptors
more easily capable of being blocked by currently available therapeutics. Instead their
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effects can then also be due to a multitude of intracellular roles that may prove more
difficult to modulate with drug targeting.
Nuclear PDGF C found in this study raises multiple questions. First, do one or
both forms of PDGF C, the full-length unprocessed and the processed growth factor
domain, have a biological function in the nucleus? Additionally, is the function of
nuclear PDGF C that of a pro-oncogenic or anti-oncogenic role? Nuclear PDGF C seen
in the chromatin bound nuclear fraction of breast cancer cells suggests that it may play a
role, either directly or indirectly in gene transcription. Further studies such as chromatin
immunoprecipitation (ChIP) could potentially identify genes that PDGF C may interact
with in the nucleus. However because of a current lack of a PDGF C antibody suitable
for immunoprecipitation, PDGF C expressed with tags such as myc-tag may need to be
utilized for ChIP studies until more suitable PDGF C antibodies are available.

A

collaborative study involving our laboratory found that a 171 invasive breast cancer
sample tissue microarray analyzed by immunohistochemical staining for PDGF C and
interpreted by a breast pathologist blinded to patient outcomes, shows that absence of
PDGF C staining or exclusively nuclear staining confers a significantly better diseasefree survival in breast cancer patients than cytoplasmic PDGF C staining (manuscript in
preparation, Figure 26). Further studies are needed to tease out the pro-oncogenic versus
anti-oncogenic signaling of PDGF C isoforms based on its subcellular localization.
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Figure 26. PDGF C expression and disease-free survival. Kaplan-Meier survival
curve depicting disease-free survival measured from date of surgery to date of locoregional recurrence, distant metastasis, or death. Statistical analysis with log-rank
test, two sided P value. Data courtesy of Dr. So Yeon Park.

Conclusion
This study has shown that increasing expression of PDGF C isoforms leads to
more aggressive characteristics in breast cancer cells in vitro and in vivo. Furthermore,
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this study reconfirms the importance of serine proteases in the processing of PDGF C
isoforms, and identifies a potent, irreversible inhibitor of PDGF C processing in cells in
vitro. Additionally this study identifies the amino acids in the hinge region of PDGF C as
crucial to subcellular localization. This is the first time to our knowledge that the splice
variant, t-PDGF C, has been shown to be secreted from transfected cells and presumably
as a heterodimer with full-length PDGF C. In addition, this study suggests that the
homodimer of t-PDGF C is an intracellular protein. This is of importance because of its
implications on paracrine signaling in cancer. As demonstrated in the proposed working
model in Figure 27, t-PDGF C can be secreted from the cell, and it can be proteolytically
processed to the growth factor domain dimer. Thus the secreted t-PDGF C may serve as
an important reservoir for PDGF C signaling. When processed to the active growth
factor domain in the extracellular milieu, it may be able to act on surrounding cells
similar to full-length PDGF C (Figure 27). Finally this study confirms a recent discovery
in the published literature, that PDGF C is also a nuclear protein (Figure 27). PDGFs
were primarily thought of extracellular signaling molecules and these recent discoveries
of PDGF C in the nuclear fraction of cells hints at a multiplicity of functions intracellular
and extracellular.
In order to fully the understand the nuances of PDGF C’s effects in disease it is
important for the research community to recognize the PDGF C mRNA splice variant and
its protein, t-PDGF C, and not simply lump the expression changes of both full-length
PDGF C and t-PDGF C into one.

It is possible that important alterations in the

expression of one or the other PDGF C mRNA splice variant, or important alterations in
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the ratio of the two are lost when treated as one in data analysis of PDGF C expression.
Additionally, further studies are needed to understand the subcellular localization of both
PDGF C isoforms, and the effects of such on the balance between pro-oncogenic and
anti-oncogenic signaling.

This has important clinical implications as future drug

targeting of aberrant PDGF C signaling in disease may need to take into account the
intracellular and extracellular roles of both PDGF C isoforms.

Figure 27. A working model for PDGF C‘s role in breast cancer.
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ABSTRACT
THE ROLE OF PDGF C AND ITS SPLICE VARIANT IN BREAST CANCER
by
ALYSSA BOTTRELL
May 2015
Advisor: Dr. Hyeong-Reh Choi Kim
Major: Pathology
Degree: Doctor of Philosophy
The PDGF family consists of four members; while PDGF A and B are secreted as
active dimers, PDGF C and D are secreted as latent dimers that undergo serine proteasemediated extracellular proteolytic activation. Gene expression analysis of breast cancer
cell lines showed that PDGF C expression is associated with Basal B subtype breast
cancer cells which have cancer stem cell-like characteristics. Furthermore, PDGF C
expression is associated with triple-negative (estrogen receptor-, progesterone receptorand HER2/neu-negative) breast cancer cells, a challenging type of breast cancer to treat.
During the course of our study, we discovered a splice variant of PDGF C encoding the
truncated PDGF C protein (t-PDGF C).

Specific aims of this dissertation are to

determine the role of full-length PDGF C (FL-PDGF C) and t-PDGF C in breast cancer
and to characterize their subcellular localizations. This study found that although tPDGF C presumably lacks the signal peptide, it is secreted as a heterodimer with FLPDGF C which can undergo extracellular proteolytic activation. Furthermore, PDGF C
was found in the nuclear fraction of breast cancer cells, suggesting an uncharacterized
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function in breast cancer. A putative nuclear localization sequence in PDGF C showed
little effect on its nuclear localization as determined by the point mutagenesis assay.
Interestingly, we found that the serine protease cleavage site in the hinge region plays a
critical role for both extracellular proteolytic processing and nuclear accumulation of
PDGF C, suggesting that the biochemical processing and the subcellular localization are
co-regulated. For the functional study, we established in vitro cell models engineered to
overexpress PDGF C isoforms or inhibit its expression. This study found that PDGF C
expression correlates with cell proliferation, invasive phenotype and anchorageindependent growth in vitro. Importantly, t-PDGF C expression further promoted PDGF
C-induced phenotypic transformation. PDGF C downregulation decreased tumor growth
and metastatic potential in vivo. Taken together, this study identified PDGF C and its
splice variant as key signaling molecules in breast cancer. In addition, once thought of as
primarily an extracellular signaling molecule, nuclear localization marks a potentially
important paradigm shift in PDGF C biology.
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